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ABSTRACT 
 Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in children 
with nearly all children infected by two years of age.  Preterm infants and infants with 
cardiopulmonary compromise or immunodeficiency are at increased risk for severe RSV 
disease.  However, a high percentage of hospitalizations due to severe RSV disease occur 
in otherwise healthy infants.  Severe RSV disease is characterized by bronchiolitis and 
airway obstruction secondary to sloughed epithelial cells, cellular debris and 
inflammatory cells that can partially occlude the airway lumen.  There is currently no 
licensed vaccine to prevent RSV infection. 
 The purpose of this study was to develop a model of RSV infection in the 
newborn lamb using a human strain of RSV, strain A2.  The pulmonary pathology and 
cellular localization of antigen was determined, in addition to the viral effect on the 
expression of epithelial innate immune genes, surfactant proteins A and D (SP-A and SP-
D respectively) and sheep beta-defensin-1 (SBD-1).  Pulmonary lesions were 
characterized by suppurative bronchiolitis with multifocal alveolar consolidation and 
peak pulmonary lesions at day 6 post-infection.  RSV infection increased expression of 
SP-A and SBD-1, which demonstrates alteration of innate immune responses caused by 
RSV A2.  Using this model, lambs were pretreated with exogenous human recombinant 
vascular endothelial growth factor (rhVEGF) prior to RSV infection.  VEGF is a known 
endothelial mitogen, but also plays an important pulmonary role in surfactant protein 
production, epithelial cell proliferation, and epithelial cell survival.  VEGF administration 
prior to RSV infection decreased both viral load and pulmonary pathology at peak 
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infection – 6 days post-infection.  In addition, VEGF increased the expression of SP-A 
and SBD-1 showing that VEGF can induce expression of important epithelial innate 
immune genes.  VEGF pretreatment altered epithelial cell proliferation in RSV infected 
animals at day 4 post-infection.  In the final part of this study, the effect of ontogeny on 
pulmonary endogenous VEGF expression was investigated.  The results of this study 
demonstrate that the expression of major VEGF isoforms are differentially regulated with 
high pulmonary VEGF mRNA expression in prenatal lamb lung and low expression in 
adult lung.  However, mRNA expression diverged from the protein profile with low 
VEGF protein expression in prenatal lung and high VEGF protein expression in adult 
lung, demonstrating tight translational regulation to maintin appropriate VEGF 
concentrations during development.
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CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
 This dissertation describes the development and characterization of a lamb model 
of human Respiratory Syncytial Virus (RSV) infection, the effect of recombinant human 
vascular endothelial growth factor (rhVEGF) pretreatment on RSV infection and the 
effect of ontogeny on expression of endogenous vascular endothelial growth factor 
(VEGF) and VEGF receptors.  This dissertation is divided into 5 chapters that include a 
General Introduction, three manuscripts that have been submitted for publication or 
published, and a General Conclusion.  Chapter 1 provides a general review of human 
RSV infection, the lamb as an animal model for RSV disease, innate pulmonary 
immunity and a brief overview of the pulmonary functions of VEGF.  Chapter 2 
characterizes the pulmonary pathology of RSV infection in the neonatal lamb using a 
human strain of RSV and alterations in epithelial innate immune gene expression.  
Chapter 3 describes the effect of rhVEGF pretreatment on viral load, pulmonary 
pathology and epithelial innate immune gene expression in the neonatal lamb model of 
RSV infection characterized in Chapter 2.  Chapter 4 describes the developmental 
pulmonary expression and cellular distribution of endogenous VEGF and VEGF 
receptors prenatally to adulthood.  Chapter 5 includes concluding remarks and future 
study directions. 
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Literature Review 
Respiratory Syncytial Virus 
Respiratory syncytial virus (RSV) is a single-stranded RNA virus in the 
Paramyxoviridae family.  RSV is the leading cause of infant bronchiolitis with 
approximately 20% of infants exhibiting bronchiolitis in their first year of life with 
almost 100% infection by 2 years of age [1].  Children often become reinfected 
throughout life, but the initial RSV infection is usually most severe and most likely to 
involve the lower respiratory tract [1].  The World Health Organization estimates that 
here are 64 million infections every year with 160,000 deaths worldwide [2].  The 
majority of cases are relatively mild, however there are populations at increased risk to 
develop severe pulmonary disease leading to hospitalization, mechanical ventilation and 
even death [3].  Infants at increased risk include premature infants and infants with 
chronic lung disease of prematurity, congenital heart disease and immune deficiency [4-
6].   
RSV – Structure 
  The RSV genome is comprised of 10 genes that encode 11 viral proteins.  There 
are two nonstructural genes (NS1 and NS2) and 9 structural genes (N, P, M, SH, G, F, 
M2-1, M2-2 and L).  The attachment (G) and fusion (F) glycoproteins are outer 
membrane proteins that participate in viral binding and entrance into target cells [2].  The 
G protein enables cell surface binding via surface glycosaminoglycans [7].  In addition, 
the G protein binds the fractalkine chemokine receptor (CX3CR1) and mimics the 
chemokine fractalkine [8].  The F protein enables virus entry by directing the fusion of 
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the virion envelope with the plasma membrane of the target cell.  The F protein may also 
initiate apoptosis by p53-dependent programmed cell death and result in epithelial 
shedding, airway obstruction and inflammation [9].  The G and F glycoproteins are the 
only virus neutralization antigens.  The SH glycoprotein plays a role in immune 
modulation and has been shown to decrease TNF-α signaling and inhibit cell death 
following infection [10].  The nucleocapsid N protein reduces cellular detection of RNA 
by encapsidating the positive-strand replicative intermediate and the genomic RNA [11].  
The L protein is the major polymerase subunit and the P phosphoprotein is a cofactor in 
RNA synthesis [12].  The M2-1 and M2-2 proteins are involved in transcription and 
transcriptional regulation [13, 14].  The matrix M protein is found along the surface of 
the inner envelope and plays a role in virion morphogenesis [15].  The NS1 and NS2 
proteins are not packaged significantly within the virion and are nonessential accessory 
proteins.  NS1 and NS2decrease type I interferon pathways and modulating the host 
response to infection [16].  Interestingly, recombinant RSVs that contain mutations in the 
NS1 and NS2 proteins replicate poorly in humans showing their important role in altering 
the host immune response [17].   
There are two major RSV groups, A and B, based on antigenic and molecular 
analysis [18].  Several reports show that children infected with group A are significantly 
older than those infected with group B with a higher frequency of fever [19].  However, 
other studies show no difference between the two groups and comparison is often 
difficult due to intercurrent issues such as prematurity and underlying conditions [20, 21]. 
RSV – Transmission and Replication 
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Inoculation of RSV occurs via aerosol or direct contact via the mucosa of the nose 
or eye [22].  Replication occurs within the epithelium of the nasopharynx for 
approximately 4-5 days.  Spread to the lower respiratory tract can follow the replication 
period.  In the lower respiratory tract, RSV targets epithelial cells of the bronchioles and 
type I pneumocytes that line the alveoli [23].  Other cells that can be infected include 
macrophages and dendritic cells [24]. 
Upon infection, the nucleocapsid and polymerase are delivered to the host cell 
cytoplasm where the genome is transcribed and replicated.  The ten viral genes are 
flanked by gene-start (GS) and gene-end (GE) sequences which function to control the 
polymerase throughout transcription.  The polymerase often dissociates from the template 
at the gene junctions, therefore the genes at the 3’ end of the genome are transcribed 
more frequently [25].  To replicate the genome the polymerase does not respond to the 
GE and GS signals and results in the transcription of a positive sense complement of the 
genome (antigenome).  The antigenome can then be used to make genome-sense RNA 
that will be encapsidated with virus nucleoprotein as synthesis occurs [2].  Virons bud 
through the plasma membrane to acquire a lipid envelope [24].   
RSV – Populations at increased risk 
The risk of severe RSV disease is increased by a myriad of factors including 
premature birth, low birth weight, large family size, male gender, lack of breast feeding, 
exposure to passive cigarette smoke and birth approximately 4 months before the peak of 
the RSV season [26].  Other infants at high risk include those with cardiovascular disease 
[27], neuromuscular diseases [28] and immune deficiency syndromes [3, 29].  RSV 
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disease related mortality rates are significantly increased in high-risk infant populations 
[30].  RSV can also cause severe disease in adults, especially patients with underlying 
cardiopulmonary disease, the elderly and immunocompromised individuals [31, 32].  In 
older adults, RSV is associated with the exacerbation of chronic obstructive pulmonary 
disease [33].  The Centers for Disease Control and Prevention estimate that 10,000 deaths 
annually are attributed to RSV infection in adults over the age of 65 years [34].   
RSV – Clinical Signs and Pulmonary Pathology 
Clinical signs secondary to RSV infection include cough, rhinorrhea, and low 
grade fever.  Infection of the lower airway causes bronchiolitis with wheezing and 
increased airway resistance.  50% or more of hospitalized infants with lower respiratory 
infection have wheezing episodes following resolution of clinical signs.  Wheezing in 
these individuals could persist until children are 11 years of age with loss of this effect by 
13 years [35].  There is controversy regarding RSV’s role in asthma development, 
although RSV is thought to induce a Th2-type response that promotes the development of 
asthma later in life.  Hypoxia secondary to pneumonia can also be an associated sign in 
RSV infected infants [24]. 
Histopathology findings attributed to RSV infection include bronchiolar epithelial 
necrosis with epithelial sloughing into the airway lumen [36].  Airway obstruction results 
from occlusion of the airway with cellular debris, mucus, neutrophils and occasional 
macrophages.  Multifocally within the bronchiolar epithelium are areas of epithelial 
proliferation and syncytial cell formation [23].  Additionally, within the bronchiolar 
lumen and bronchiolar epithelium are infiltrates of macrophages, neutrophils.  The 
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bronchiolar subepithelial area and adventitia are infiltrated by T, B cells and occasional 
plasma cells, depending on the stage of disease [24].  The pathogenesis of the lesions will 
be discussed in a later section. 
RSV:  Therapeutics and therapeutic targets 
At this time there are no effective vaccines for RSV infection.  Palivizumab 
(Synagis), a humanized monoclonal antibody, is the only approved prophylactic 
treatment for infants at high risk.  Palivizumab is directed against the F surface 
glycoprotein.  Palivizumab reduces the frequency of severe RSV disease by 50% in 
children at high risk and therefore decreases the development of bronchiolitis and 
subsequent hospitalization [37, 38].  A formalin inactivated vaccine formulated in the 
1960’s in the United States failed to protect children against infection and actually 
enhanced disease during natural infection in infants and toddlers.  Two infants that were 
immunized with the vaccine died upon subsequent infection.  High titers of RSV were 
recovered from these infants [39].  In vivo studies in animals models have shown that 
unlike natural infection, formalin inactivated RSV leads to development of a Th2 
memory response [40, 41].  Clinical manifestations of enhanced disease included 
bronchoconstriction and severe pneumonia.  Pulmonary histology of patients with 
enhanced disease have increased peribronchiolar eosinophils [42] and deposits of 
antibody complexed with virus in affected tissue [43].  Given the outcome of this vaccine 
there have been huge efforts to understand vaccine enhanced disease and research to 
determine the best method for vaccination against RSV. 
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Pathogenesis of RSV disease 
Why some individuals infected by RSV develop severe bronchiolitis and airway 
occlusion while others do not is a key question in understanding the pathogenesis of RSV 
disease and in the development of future therapeutic targets.  There are a wide variety of 
host factors and viral factors that contribute to disease outcome.  The host and viral 
factors that contribute to disease will be discussed in more detail in the following 
sections. 
Recognition of RSV by the host and activation of the innate immune response 
 The activation of the host innate immune response during RSV infection depends 
on complex signaling events.  Pattern recognition receptors (PRRs) detect viral binding 
and entry into epithelial cells, thereby stimulating responses that trigger the production of 
cytokines, chemokines and other antimicrobial products [44].  The most well-known 
PRRs are the Toll-like receptors (TLRs) that sense a wide variety of microbial ligands at 
the cell surface or within intracellular endosomes.  A wide variety of TLRs have been 
reported to activate innate immune responses in RSV infection including TLR2 [45, 46], 
TLR4 [47], TLR3 [48], TLR6 and TLR7.  A study using TLR4-deficient mice showed 
impaired RSV clearance, impaired IL-12 production and decreased natural killer cell 
function [47], showing the importance of TLRs in triggering anti-viral responses.  
Although the overall effect of TLR4 on disease pathogenesis is unclear, a recent report 
demonstrated TLR4 polymorphisms in high-risk infants were linked to symptomatic RSV 
disease [49].  Other cells, such as immature dendritic cells can sense virus through toll 
like receptors (TLRs), which can trigger T- and B-cell responses [50].  Additionally, viral 
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replication products are also recognized by cytoplasmic sensing pathways, including 
retinoic acid induced gene (RIG)-I and melanoma differentiation antigen (MDA)-5 
proteins.  RIG-I is a highly inducible cytoplasmic RNA helicase that induces the 
expression of Type I interferons and other antiviral mediators after binding double-
stranded RNA [51].  MDA5 can be activated by long double stranded RNA generated 
during infection to drive IFN responses [52].  
Chemokines and cytokines 
 Chemokines are involved in chemotaxis of recruited immune cells at the site of 
infection.  Chemokines are classified into three groups termed C, C-C, and C-X-C based 
on the number and spacing of conserved NH2-terminal cysteine residues.  In addition 
there is a fourth group, the C-X3-C group which is composed of large, membrane bound 
glycoproteins [53].  The role of chemokines and their effect on RSV disease severity is 
still unclear.  Nasal and tracheal aspirates from RSV infected infants have significant 
expression  proinflammatory cytokines including,  regulated on activation normal T cell 
expressed and secreted (RANTES), macrophage inflammatory protein (MIP-1α) and 
monocyte chemotactic protein (MCP-1) [54, 55].  The expression of these chemokines 
correlates to the number of leukocytes present in the sample [56].  MIP-1α appears to be 
an important initiator of the inflammatory response in RSV infection.  MIP-1α knockout 
mice develop less severe pulmonary inflammation when infected with RSV as compared 
to wild-type mice [57].  In addition, polymorphisms of the MIP-1α receptor have been 
reported with RSV bronchiolitis in infants [58].   
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 Epithelial cells play an important role in promoting and regulating inflammatory 
responses.  Proinflammatory cytokines produced by RSV infected epithelial cells include; 
IL-6, IL-8, TNF-α, IFN-α and IFN-β [59].  In addition, growth factors such as GM-CSF 
and G-CSF are produced by RSV infected epithelial cells [60].  Higher levels of both IL-
6 and IL-8 correlate with an increased disease severity [61].  Cytokines associated with 
adaptive responses will be discussed further in the adapative immune response section.   
 Numerous viruses alter or modify expression of chemokine and cytokine 
responses and thereby alter host responses.  A recent study examined the expression of 
suppressor of cytokine signaling (SOCS) protein in vitro during RSV infection in human 
bronchiolar epithelial cells.  SOCS proteins negatively regulate chemokine and cytokine 
responses [62].  This study found that the RSV G glycoprotein upregulated SOCS 
expression resulting in a decrease in type I IFNs and interferon stimulated gene (ISG) 
expression [63].  A decrease in type I IFNs facilitates viral replication due to reduced 
expression of downstream products such as the GTPase Mx1 (myxovirus resistance 1) 
protein,  ISG15 (IFN-stimulated protein of 15 kDa), RNaseL (ribonuclease L) and PKR 
(protein kinase R) [64].  Mx GTPases are located near the smooth endoplasmic reticulum 
and survey exocytic events and trap essential viral components to prevent early viral 
replication [65].  ISG15 prevents virus-mediated degradation of IFN transcription factors 
thereby increasing IFNβ expression [66].  Additionally, ISG15 acts as a cytokine to 
modulate the immune response [67].  RNaseL is activated through by-products generated 
by OAS proteins.  OAS proteins synthesize 2’,5’-linked phosphodiester bonds to 
polymerize ATP into oligomers of adenosine.  Activated RNaseL mediates RNA 
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degradation [64, 68].  PKR proteins respond to environmental stresses in order to regulate 
protein synthesis.  PKR phosphorlyates EIF2α which prevents the recycling of GDP and 
stops translation [64]. 
IFN-α and IFN-β are Type I interferons.  Type I IFNs are regulated by 
transcription factors such as interferon regulatory factor 3 (IRF-3) and nuclear factor-κB 
(NF-κB) [69].  As previously mentioned, Type I interferons can also be induced by TLR 
activation, specifically TLR3 in RSV infection [11].  In addition Type I interferons can 
be produced by dendritic cells and macrophages [70].  Type I interferons play a role in 
antiviral host defense in addition to promoting interferon-stimulated genes (ISG), natural 
killer (NK) cells, and dendritic cell maturation [71].  As indicated, RSV proteins 
modulate the immune response to better enable viral replication and survivability.  The 
nonstructural proteins, NS1 and NS2 can also down-regulate type I IFNs by a variety of 
mechanisms that inhibit the formation of downstream  signaling complexes such as 
ISG15, Mx1, RnaseL and PKR [72]. 
Inflammatory cells 
 Chemokines released by airway epithelial cells recruit leukocytes from the 
circulation to the site of infection.  Neutrophils are the first inflammatory cell to arrive, 
between days 1-6 days post-infection.  Lymphocytes infiltrate between days 4-11 with 
the greatest number of lymphocytes at day 11 [73].  IL-8 is the primary neutrophil 
chemoattractant secreted by epithelial cells.  Neutrophils are present within the 
bronchiolar lumen and epithelium and have the ability to adhere to epithelial cells thereby 
enhancing epithelial damage [74, 75]. 
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 Alveolar macrophages are critical for removal of debris, apoptotic cells and also 
to remove opsonized material.  A recent study examined the role of alveolar macrophages 
in RSV disease using New Zealand black mice, which have decreased number and 
function of alveolar macrophages.  These RSV-infected mice have increased viral load 
and airway occlusion.  Airway occlusion is a key feature of RSV disease, indicating the 
importance of macrophages in the removal of this cellular debris [76].   
 Natural killer (NK) cells exhibit nonspecific cytotoxicity against cells that express 
stress markers.  NK cells produce IFN-γ and regulate activity of other innate and adaptive 
immune responses [77].  Although the role of NK cells in viral infection is important, NK 
cell activity in RSV infection is largely unknown.  NK cells have not been detected in 
autopsy studies from infants with fatal RSV bronchiolitis [78]. 
Adaptive immune responses to RSV 
 The humoral immune response to RSV infection results in production of anti-
RSV antibodies of the IgM and IgG isotype in addition to secretory IgA in the respiratory 
tract.  Antibody responses are primarily against the surface glycoproteins, G and F, with 
virus neutralization being mediated predominantly by anti-F glycoprotein antibodies.  
Primary antibody responses to RSV peak approximately 3-4 weeks post-infection and 
then decline.  Strong antibody responses occur within 2-3 days following re-infection.  
Antibody responses are not completely protective as individuals with high neutralizing 
antibody titers are often reinfected with RSV.  Therefore a variety of other host factors 
determine whether the host clears the infection. 
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 Cell mediated immune responses play a vital role in removal of virally infected 
cells.  Viral replication lasts for weeks to months in immunocompromised individuals 
infected with RSV.  Infants with RSV infection have weak antiviral cytotoxic responses 
[78].  Pulmonary tissue from fatal infant RSV infections failed to show infiltration of 
CD4+ or CD8+ lymphocytes.  Why these infants lacked cytotoxic lymphocytes is not 
completely understood, but may be related to immature lymphocytes or alterations with 
antigen presentation by immature dendritic cells [79].  Cytokines associated with T 
lymphocytes including, IL-2, IL-4, IL-5, IL-13, IL-17 and IFNγ are present at low 
concentrations during the peak of infection in infants.  This indicates that important 
cytotoxic antiviral responses are present at only low levels or lacking in infants [78]. 
The neonatal immune system 
The peak hospitalization for RSV disease is approximately 2 months of age.  RSV 
induces disease in infants earlier than other respiratory viruses, such as influenza and 
rhinovirus [80].  There are a variety of factors that contribute to disease pathogenesis in 
this young age group, including pulmonary anatomy (smaller airways), immunologic 
immaturity and maternal immunity.  Smaller airways are more prone to occlusion.  
Immune responses are somewhat dampened compared to those in older children.  For 
example, young infants have fewer number of lymphocytes in peripheral lymphoid tissue 
as compared to adults [24].  In addition, neonatal dendritic cells are less efficient in 
promoting T-cell proliferation in response to antigen stimulation and produce fewer 
cytokines following RSV infection [81].  Cellular cytotoxic responses against RSV were 
detected in less than 40% of infants under 5 months of age compared to 65% in children 
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6 months to 2 years [82].  In vitro studies using alveolar macrophages from infants 
exhibit multiple deficiencies in function including, impaired chemokine release, oxidative 
burst and phagocytosis [83].   
It is well documented that young infants mount a poor antibody response to viral 
infection or immunization [84, 85].  In fact, the serum and mucosal antibody response to 
the G and F glycoproteins of young infants to RSV infection is approximately 15-25% 
that of older infants and children [86].  The reason for the decreased antibody responses 
is due to both high levels of maternally acquired RSV serum antibodies as well as 
immunologic immaturity.  Given these less effective acquired immune responses, the 
innate immune response is vitally important in controlling initial infection. 
Pulmonary Host Defense and Innate Immunity 
 The lung is constantly exposed to inhaled particulates, pathogens and allergens.  
Therefore, an extensive network of defense mechanisms are necessary to protect the lung 
from damage.  These mechanisms include: the epithelial barrier, mucociliary apparatus, 
antimicrobial products present with the surfactant layer and airway surface liquid, and 
alveolar macrophages.  Epithelial cells also produce a wide variety of products that have 
inflammatory and immunoregulatory functions.  The innate host pulmonary defense is 
composed of many systems that serve to:  1) detect pathogens and remove them, 2) signal 
immune cells to the site and 3) provide responses that will stimulate an optimal adaptive 
immune response.  The following sections will describe the functions of the epithelial 
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derived products, surfactant proteins and β-defensins, in pulmonary immunity and their 
importance in RSV infection. 
Antimicrobial peptides - Defensins 
Pulmonary antimicrobial peptides include members of the defensin and 
cathelicidin classes.  Antimicrobial peptides have broad-spectrum activity against Gram-
positive and Gram-negative bacteria, viruses, fungi and yeast.  Three families of defensin 
peptides have been identified including the α-defensins, β-defensins and σ-defensins.  In 
humans, the α-defensins are expressed in Paneth cells of the intestine, azurophilic 
granules of neutrophils, and other epithelial surfaces such as the vagina, cervix and 
fallopian tubes [87].  The β-defensins are present in mucosal epithelial cells, mucosal 
secretions and granulocytes.  The σ-defensins have been identified in leukocytes from 
nonhuman primates - rhesus macaque and olive baboon [88, 89].  Cathelicidins are 
antimicrobial peptides that are derived from proteins.  In humans, only one cathelicidin 
has been characterized, LL-37, which is derived from the C-terminal end of the human 
CAP18 protein (hCAP18) [90].  The cathelicidin present in sheep is SMAP that is present 
within leukocytes (sheep myeloid antimicrobial peptide) [91]. 
β-Defensin Structure 
β-defensins are cationic peptides with a broad-spectrum of antimicrobial activity.  
They are secreted at a wide variety of epithelial surfaces including the skin, gingiva, 
intestine, urogenital tract, kidney and respiratory epithelium [92].  β-defensins have three 
disulphide bonds between six conserved cysteine residues, which results in a triple-
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stranded β-sheet structure and a β-hairpin loop containing cationic charges [87].  β-
defensins are small – the preprotein is approximately 65 amino acids, which is then 
cleaved to form a mature peptide that is approximately 45 amino acids [93].  In addition 
to their small size, they have a high concentration of cationic residues (arginine, lysine, 
histidine) which enable them to interact and alter cellular membranes of microbial agents.  
The cholesterol content of mammalian cells appear to protect host cells from beta 
defensin-mediated damage [94].     
β-Defensin Expression 
The β-defensin gene has two exons that encode for a single gene product.  In 
humans, there are five β-defensins produced by epithelial cells; human β-defensin 
(HBD)-1 [95], HBD-2 [96], HBD-3 [97], HBD-4 and HBD-5 [98].  HBD-1, -2, and -3 
are produced by epithelial cells of the lung.  HBD-1 expression in the lung is constitutive 
whereas HBD-2 and HBD-3 are inducible by pro-inflammatory stimuli induced by 
bacteria, viruses and microbial products [99, 100].  Inflammatory mediators which 
activate toll like receptors (TLRs) can upregulate β-defensin expression.  Airway 
epithelial cells expresses TLR1 through TLR6 and TLR9 [101], therefore a wide variety 
of stimuli from bacterial LPS to viral RNA can induce β-defensin expression [102].  In 
addition, expression of β-defensins is developmentally regulated in late gestation and 
throughout the neonatal period, which can lead to increased susceptibility to respiratory 
tract infection in younger animals that have lower expression [103].  β-defensins have a 
critical role in host defense either as constitutive or inducible components of the 
epithelial barrier [92]. 
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The nomenclature of β-defensin genes is rather confusing.  The genes were 
originally numbered sequentially based on discovery; however the human gene name was 
changed to the gene name of the mouse ortholog, if an ortholog existed.  If an 
orthologous gene had not been identified, then the human gene was assigned a number 
greater than 100.  Therefore the human gene DEFB2 encoding the peptide HBD-2 was 
changed to DEFB4 due to its orthology to mouse Defb4 [93].  Murine β-defensins 
(MBD) including MBD-1, -2, -3, and -4 have been detected in mucosal tissue with 
antimicrobial properties similar to human β-defensins [104].  Recently, MBD-14 was 
discovered to be the orthologue of HBD-3 [105] and exhibits similar antimicrobial and 
chemotactic activity to that of HBD-3.  Two ovine β-defensins have been discovered, 
sheep beta-defensin (SBD) -1 and SBD-2, both of which are highly expressed in the lung, 
in addition to other tissues such as intestine [103].  SBD-1 is inducible in parainfluenza-3 
and RSV infection [106, 107]. 
β-Defensin Activities 
 Antimicrobial 
β-defensin antimicrobial activity is predominantly mediated by electrostatic 
binding of the cationic peptide to the outer surface of the pathogen with insertion of a 
peptide into the cytoplasmic membrane, resulting in cellular leakage [87]. 
 The antiviral effects of defensins are attributed to both direct interactions with the 
virus and through interaction with the target cell.  β-defensins have been shown to have 
anti-viral activities on several viruses including HIV-1, vaccinia virus, adenovirus, 
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rhinovirus, herpes simplex virus, RSV and influenza virus [98, 108].  In influenza virus 
infection, HBD-3 inhibits hemagglutinin-mediated fusion to prevent infection of the host 
cell [109].  The antiviral activity of defensins has been most studied in HIV infection.  
Studies show that HBD-2 and HBD-3 have anti-HIV activities through direct interaction 
with the virus and also by indirectly altering the target cell.  Interestingly, HBD-2 inhibits 
the formation of early reverse-transcribed HIV DNA products but does not affect cell-cell 
fusion [110].  A recent study demonstrated in vitro and in vivo induction of β-defensin 
expression following RSV infection [111].  The induction was dependent on NF-κB 
activation of tumor necrosis factor (TNF).  During RSV infection TNF is produced by 
epithelial cells and macrophages.  Increased TNF could therefore increase HBD-2 
production.   Also this study demonstrated that HBD-2 inhibited RSV cellular entry, with 
loss of antiviral activity following HBD-2 silencing using siRNA [111].   
 Chemotaxis Activity and Immune Regulation by Beta Defensins 
 β-defensins have chemotactic activity for monocytes, immature dendritic cells, 
and T cells.  In addition, β-defensins can induce cytokine production by monocytes and 
epithelial cells.     
 β-defensins have a role linking innate and adaptive immune responses [112].  
Mouse β-defensin 2 is chemotactic for immature dendritic cells and memory T cells 
through the chemokine receptor CCR6 [105].  HBD-3 and -4 induce mast cell chemotaxis 
and degranulation [113]. 
Summary 
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In summary, β-defensins have important anti-viral activities in the lung.  β-defensins are 
developmentally regulated which may account for decreased innate immune responses in 
young individuals, making them more susceptible to RSV and other infections. 
Surfactant Proteins A and D - Collectins 
The primary function of the lung is to adequately maintain oxygenation of the 
blood for tissue distribution.  For gas exchange to occur in the lung the alveoli must 
remain inflated throughout respiration, this is especially important during expiration.  
Surfactant proteins function to prevent alveolar collapse by reducing the surface tension.  
Surfactant is composed primarily of the phospholipid, dipalmitoyl phosphatidylcholine 
(DPPC), which comprises approximately 40-45% of the total surfactant mass.  Other 
lipids including phosphatidylcholines, phosphatidylglycerol and cholesterol make up the 
remaining surfactant mass.  Surfactant proteins B and C (SP-B and SP-C) are important 
in reducing surface tension and co-assemble with other surfactant lipids in the type II 
epithelial cell.  SP-A and SP-D are secreted by a different pathway and serve varying 
functions which will be detailed later [114, 115].  Following surfactant secretion, the 
surfactant is organized into structures called tubular myelin, mono- and multi-layered 
sheets and vesicles [115].  SP-B is the only essential surfactant protein in reducing 
surface tension, however SP-A and SP-D play an important role in surfactant homeostasis 
[116, 117].  SP-A and SP-D are members of the collectin family and are primarily 
involved in innate immune defense [118].  Recent studies show SP-C also interacts with 
infectious agents and pattern recognition molecules, and is therefore also involved in 
pulmonary innate immunity [117].   
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Collectins are large, oligomeric glycoproteins with four domains; a cysteine-
containing N-terminal portion, a collagen-like domain, an α-helical coiled neck and a C-
type lectin domain or carbohydrate recognition domain (CRD).  With SP-A the subunits 
trimerize to form a single subunit that are then linked by disulfide bonds into oligomers 
of up to six subunits [118, 119].  SP-D is usually composed of four subunits in a 
cruciform shape, however the number of subunits varies with species [120].  The more 
numerous the CRD domains (which is determined by the number of subunits), the higher 
the binding avidity to carbohydrate surfaces [118]. 
SP-A and SP-D bind to a wide range of microorganisms including Gram-negative 
bacteria, Gram-positive bacteria, yeast, fungi, and viruses [119].   
Surfactant Protein A&D Receptors 
 The best characterized SP-A receptor is the SPR-210 (surfactant protein receptor 
210 kDa) found on type II cells and alveolar macrophages that mediates uptake and 
killing of pathogens and inhibition of phospholipid secretion [121, 122].  During 
homeostatic conditions, SP-A and SP-D block pro-inflammatory mediators by binding to 
the signal-inhibitory protein α (SHIPα) receptors on macrophages through their CRDs.  
When the collectins bind microbes, the collagenous tails interact with calreticulin/CD91 
on the cell surface thereby stimulating phagocytosis and pro-inflammatory responses 
[123].   
Surfactant Proteins A&D Expression 
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SP-A and SP-D are primarily produced in the lower airways but are also 
expressed in the upper airways; including the trachea and the Eustachian tube [124].  SP-
D is expressed in epithelial cells, such as the prostate and cervical mucosa [125].  
Surfactant protein synthesis by alveolar type II cells begins at approximately 75% of 
gestation and is regulated by a wide variety of hormones, growth factors and cytokines 
[126].  There is complex regulation during fetal lung maturation as shown by the effect of 
glucocorticoids on lung development and surfactant synthesis.  Glucocorticoids at low 
concentrations increase SP-A mRNA expression and protein, however high 
glucocorticoid concentrations decrease expression [127, 128].  SP-A and SP-D are 
expressed constitutively in the lung and expression can be increased following lung 
injury and epithelial cell activation. 
Surfactant Proteins A&D – Antimicrobial functions 
Antimicrobial binding is predominantly mediated by the CRD however there are 
reports that some organisms, such as herpes simplex virus, associate with the N-linked 
oligosaccharides [129].  The CRD binds to microorganisms by recognizing widely 
spaced, repetitive sugar arrays.  The binding of pulmonary pathogens can lead to the 
formation of large microbial aggregates that result in the inhibition of infectivity.  In 
addition, SP-A or SP-D can modulate the function and activity of alveolar macrophages 
and neutrophils thereby contributing to a more efficient clearance and killing of 
microorganisms [121].  SP-A is essential for host defense as shown by SP-A knockout 
mice that are susceptible to infection from each class of pathogen [130]. 
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In viral infection, SP-A and SP-D can function either by direct anti-viral activity 
or by immune modulation [131].  The interaction of the pulmonary collectins with 
influenza virus is the most widely studied.  SP-A interacts with influenza viral proteins 
through an N-linked oligosaccharide on the CRD rather than binding the carbohydrate 
binding site [132].  SP-D binds influenza virus through interactions of the viral 
haemagglutinin protein and neuraminidase envelope glycoprotein with the CRD [133].  
In RSV infection, SP-A binds to the fusion glycoprotein in a calcium-dependent manner 
while SP-D binds the G protein to decrease viral infectivity [134-136].  Numerous 
pulmonary conditions are associated with an acquired deficiency of SP-D including, 
chronic smoking, chronic obstructive lung disease and cystic fibrosis [137, 138].  
Individuals with these conditions are predisposed to viral respiratory diseases which 
worsen their condition. 
Surfactant Proteins A&D – Immune functions 
SP-A and SP-D modulate pulmonary inflammatory responses and primarily 
dampen inflammation during normal pulmonary homeostasis.  Pro-inflammatory or anti-
inflammatory signals stimulated by collectins depend on the cellular receptor that is 
activated, in addition to whether the interaction is with a host cell or a pathogen [123].  
Regulation of inflammatory mediators is important to minimize tissue damage and 
maintaining adequate gaseous exchange.  SP-A modulates the production of 
inflammatory cytokines produced by alveolar macrophages and thereby may also mediate 
the transition from innate to adaptive immunity [139].  SP-A reduces TNF-α production 
in vitro by LPS stimulated macrophages [140].  However, other studies show that SP-A 
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enhances TNF-α production in vitro [141], showing differential modulation depending on 
the environmental conditions.  The collectins can also modulate the production of 
reactive oxygen and nitrogen species by alveolar macrophages depending on the 
activation state of the cell and the pathogen present [121].  SP-A and SP-D can stimulate 
directional actin polymerization and chemotaxis of alveolar macrophages to increase 
uptake of organisms.  SP-A enhances LPS-mediated nitric oxide formation in alveolar 
macrophages that have been activated by IFN-γ but inhibit LPS-mediated production of 
nitric oxide in resting alveolar macrophages isolated from pathogen free rats [139].  SP-A 
and SP-D also function in the clearance of apoptotic cellular debris, which is important in 
limiting inflammation induced by lung injury [142].  Following uptake of apoptotic cells, 
macrophages release anti-inflammatory mediators such as IL-10, transforming growth 
factor β and prostaglandin E2 [143].  Additional immune functions have been attributed to 
SP-A, such as regulation of dendritic cell function [144, 145] and inhibition of T cell 
proliferation by its collagen-like domain [146].  
 
Surfactant Proteins A&D in RSV Disease 
Only recently has the importance of SP-A and SP-D become evident in viral 
infections.  In humans there are two SP-A genes (SP-A1 and 2) with multiple haplotypes.  
Certain haplotypes have been associated with increased risk of RSV infection, while 
other haplotypes are associated with protection from severe disease [147].  The 
importance of SP-A in RSV clearance was shown in an SP-A knockout mouse model.  
SP-A knockout animals inoculated with RSV showed decreased viral clearance, 
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increased cytokine levels and decreased superoxide and hydrogen peroxide generation by 
macrophages [148].   
Interestingly bronchoalveolar lavage fluid from human infants with severe RSV 
infections reveal decreased levels of SP-A protein [149].  A recent in vitro study showed 
that although there is marked increase in SP-A gene expression without a resultant 
increase in protein production [150].  This study suggests that RSV may have a role in 
altering SP-A homeostasis and thereby innate defense mechanisms.  Human infants with 
polymorphisms in the SP-A or SP-D geneshave increased RSV severity [151, 152].   
Summary 
Surfactant proteins are important in pulmonary homeostasis and defense.  SP-A 
and SP-D have important anti-viral actions and serve to minimize pulmonary damage 
during infection.  Alteration in collectin expression by RSV infection or pulmonary 
immaturity may hinder an important component of the pulmonary innate immune 
response and lead to increased infection or more severe disease. 
Animal models 
There are numerous animal models used to study RSV disease. The cotton rat and 
mouse are the most commonly used.  Many rodent models do not produce robust RSV 
disease.  The cotton rat is an good small rodent model of RSV disease as infected animals 
develop both upper and lower respiratory infection with peak replication of virus at day 4 
with clearance by day 7 [153].  Pulmonary lesions in the cotton rat include peribronchitis 
and perivasculitis with an interstitial pneumonitis.  However, the infection does not 
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induce significant clinical signs [154].  Mouse models are frequently used due to 
availability of gene knock-out specific mice as well as reagent availability.  BALB/c mice 
require a high dose of virus to become infected and develop mild inflammation, mostly 
surrounding blood vessels and not centered on airways [23].  The pulmonary pathology in 
mice does not exactly replicate that of humans, as inflammation is not centered on the 
airways.  However, using different strains of RSV may enable better comparison.  For 
example, BALB/c mice infected with RSV line 19 strain but not with strain A2 
demonstrate increased viral load, increased IL-13, and increased bronchiolar mucus 
expression [155].  Increased airway mucus is a finding in human RSV infection and 
contributes to airway obstruction.  Infant ferrets are susceptible to upper and lower 
respiratory infection by RSV and show age dependent susceptibility, similar to humans 
[156].  A rhesus monkey model developed mild clinical disease, however symptoms of 
more severe disease such as wheezing or dyspnea were not observed [157].  The costs 
associated with obtaining and housing primates hinders their frequent use in RSV studies.  
Other animal models include the guinea pig, hamster, chinchilla, squirrel monkeys, owl 
monkeys, marmosets and mink [158].  
Lamb model 
The lamb model represents an excellent model of human RSV disease.  Lambs are 
susceptible to both human and bovine strains of RSV and develop similar pulmonary 
lesions to those of human infection, including bronchiolitis, airway plugging and alveolar 
consolidation [107, 159, 160].  Clinical disease in lambs includes fever, cough and 
occasional wheezing.  In a study using bovine RSV, preterm lambs exhibited more severe 
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disease than term lambs, thereby representing an important population that is at increased 
risk in human medicine [161].  Importantly, pulmonary development in lambs is similar 
to humans.  Alveologenesis begins prenatally in lambs as it does in humans.  In contrast, 
alveologenesis occurs post-natally in rodents.  The respiratory epithelia of airways, distal 
bronchioles and alveoli of sheep are similar to those of human lung, whereas rodents 
have a large number of Clara cells (50-60%) [162, 163].  Sheep also have submucosal 
glands which produce important innate immune products, whereas rodents do not.  
Finally, sheep have similar airway structure and function as humans with similar airflow, 
resistance and compliance [164].  There are numerous ovine pulmonary models of human 
disease including asthma [164], pulmonary hypertension[165], smoke inhalation [166], 
etc, that take advantage of the pulmonary similarity.   
Pulmonary Vascular Endothelial Growth Factor 
Overview 
Vascular endothelial growth factor (VEGF) is a well known proangiogenic factor 
that also plays an important role in embryogenesis [167-169], skeletal growth [170, 171] 
and reproductive functions [172-174].   Mice lacking one or both VEGF-A alles die 
during gestation, demonstrating that VEGF expression is critical to embryologic 
development [168, 175].  In addition to VEGF’s important roles in physiologic 
angiogenesis, VEGF has a role in pathologic angiogenesis including wound healing [176, 
177], tumor vascularization [167, 178], and neovascularization associated with numerous 
ocular diseases [179, 180].  VEGF activates endothelial nitric oxide synthase which 
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mediates the permeability effects of VEGF [181].  The permeability activity of VEGF 
plays an important role in inflammation [182].  Numerous nonendothelial cells express 
VEGF including bone marrow progenitor cells [183], type II alveolar epithelial cells 
[184], hepatocytes, kidney podocytes, cardiac and skeletal muscle [185], lymphocytes 
[186], dendritic cells [187], and others.  The focus here will be on VEGF expression in 
the lung and VEGF’s role in physiologic and pathologic processes within the lung.  The 
lung has one of the highest VEGF mRNA expression levels of all the body tissues [188].   
The VEGF gene family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D and 
placental growth factor.  VEGF-A is usually referred to as VEGF and is organized as 
eight axons separated by seven introns.  Alternative exon splicing results in four 
predominant angiogenic isoforms; VEGF121, VEGF165, VEGF189, and VEGF206 with 
VEGF165 being the predominant isoform [189, 190].  VEGF165 is a heparin-binding 
homodimeric glycoprotein of 45 kDa [191].  VEGF189 and VEGF206 bind heparin with 
high affinity but VEGF121 does not bind heparin due to its acidic nature.  VEGF121 is a 
freely diffusible protein while VEGF189 and VEGF206  are sequestered within the 
extracellular matrix (ECM) [192].  VEGF165 has intermediate properties because it is both 
secreted and bound to the cell surface and extracellular matrix [193].  Extracellular 
matrix isoforms can be displaced and become active by heparin or heparinase which 
prevent them from binding to heparin-like moieties [192].  Plasmin can cleave ECM 
isoforms to allow diffusion, thereby serving a regulatory role during physiological and 
pathological angiogenic processes [194].   
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VEGF regulation at the mRNA level is complex with the formation of various 
isoforms in addition to anti-angiogenic isoforms.  Anti-angiogenic isoforms result from 
alternative distal splice site selection in exon 8, which encodes an alternate COOH-
terminal sequence.  The anti-angiogenic protein has the same length as the pro-
angiogenic isoform but a different COOH-terminal amino acid sequence and function 
[195].  Anti-angiogenic isoforms are listed with the letter “b” following the amino acid 
number, for example VEGF165b.  The COOH terminus of VEGF determines the proteins 
mitogenic potency and therefore a different terminus would relate to varied function, 
which are thought to regulate the angiogenic functions [196].  In vivo studies show that 
VEGF165b significantly inhibit VEGF165 mediated activation of VEGF Receptor-2 
(VEGFR-2) inhibiting VEGF mediated vasculogenesis [195].  A recent study examined 
the effect of VEGF121b administration in a colon cancer allograft model system.  There 
was marked reduction of tumor size and microvascular density in animals treated with 
VEGF121b.  Therefore anti-angiogenic properties are not attributed to just VEGF165b but 
appear to be a common property of all isoforms with the altered terminal sequence [197].  
 VEGF binds two tyrosine kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-
1).  Both receptors have seven immunoglobulin-like domains in the extracellular domain 
and a single transmembrane region [198-200].  An alternatively spliced form of VEGFR-
1, a soluble form, has been shown to be an inhibitor of VEGF activity [201].  VEGFR-1 
is essential in embryogenesis as evidenced by Flt-1-/- mice which die in utero [202].  
Receptor-1 knockout mice have endothelial cells that fail to organize into vascular 
channels with evidence of excessive disorganization [203].  VEGFR-2 is the major 
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mediator of the mitogenic, angiogenic and permeability effects of VEGF.  VEGFR-2 null 
mice fail to develop blood islands and lack organized blood vessels resulting in in utero 
death [204].  VEGF also interacts with a family of co-receptors called neuropilins (NP).  
NP1 enhances the binding of VEGF165 by presenting it to VEGFR-2 in a way that 
enhances the effectiveness of the signal transduction pathway [205].   
VEGF Regulation 
 VEGF is regulated by numerous factors including hypoxia, growth factors, 
cytokines and other extracellular molecules [206].  Hypoxia is the most well known 
regulator of VEGF transcription.  Under normoxic conditions, the alpha subunit of 
hypoxia inducing factor-1 (HIF-1) is targeted for prolyl hydroxylation which then leads 
to ubiquitination and degradation of HIF-1.  However, under hypoxic conditions prolyl-
hydroxylase is inhibited, enabling HIF-1 to enter the nucleus and binds to the hypoxia 
responsive elements in the promoters of hypoxia-responsive genes, including the VEGF 
promoter [207, 208].  VEGF is also induced by other growth factors and cytokines 
including IL-1, IL-6, platelet derived growth factor, TNF-α, TGF-β and fibroblast growth 
factor-4 [209-211]. 
VEGF in Pulmonary Development 
 VEGF has a complex role in lung development as VEGF is necessary for normal 
development of endothelial and epithelial components and plays a part in directing 
correct structural formation [212].  During embryogenesis, VEGF is localized within 
epithelial cells and within the subepithelial matrix.  At the time of branching, VEGF is 
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concentrated at the terminal airways and stimulates neovascularization revealing that 
branching and vessel formation are interrelated [213].  The location of expression in 
addition to the concentration of protein, is crucial to development or maldevelopment.  
Embryonal pulmonary overexpression of VEGF results in dysmorphogenesis [214] 
whereas a decrease in lung VEGF results in loss of septal formation and emphysema 
[169].     
VEGF’s Pulmonary Functions 
VEGF has varied functions in the lung including regulation of surfactant protein 
synthesis, epithelial cell homeostasis and epithelial cell proliferation.  VEGF acts on type 
II pneumocytes via the VEGFR-2 to stimulate surfactant protein production resulting in 
lung maturation and protection [215, 216].  Interestingly, high doses of dexmethasone, 
often given to neonates to increase lung maturation and surfactant production, suppress 
VEGF levels and VEGFR-2 expression [217, 218].  VEGF can stimulate growth of 
airway epithelial cells in vitro and may be important in epithelial cell repair [219, 220].  
VEGF also serves as an anti-apoptotic factor for epithelial cells.  Rats chronically 
exposed to a VEGF receptor blocker (SU5416) had increased alveolar septal cell 
apoptosis resulting in pulmonary emphysema [221].  A recent study in sheep 
demonstrated enhancing effects and alteration of the immune response [222].  In this 
study, administration of pulmonary VEGF induced the expression of IL-6, IL-8, TNFα, 
RANTES, MCP-1 and IFNγ by 32 hours following administration. 
VEGF in pulmonary disease 
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The role of VEGF in pulmonary disease is varied and often complex.  Elevated or 
reduced levels of VEGF have been measured in numerous respiratory disorders including 
pulmonary hypertension [223], acute lung injury [224, 225], COPD [226] and RSV 
disease  [227] in addition to many others.  In a fetal sheep model of pulmonary 
hypertension, VEGF levels are reduced and treatment with VEGF165 reduces the severity 
of the pulmonary vascular remodeling [223].  Acute lung injury results in the disruption 
of the alveolar-capillary membrane leading to disruption of oxygen exchange resulting in 
interstitial and alveolar edema.  Patients with acute lung injury have higher plasma VEGF 
levels compared to control patients.  High plasma VEGF levels were associated with 
increased mortality [224].  However, other studies measure decreased VEGF levels in 
lung tissue from acute respiratory distress patients and VEGF levels are negatively 
correlated to apoptotic endothelial cell counts [225].  A study using transgenic mice 
showed VEGF production induced by IL-13, led to protection against hyperoxic acute 
lung injury [228].  In patients with COPD there is progressive loss of lung tissue with 
emphysematous change.  These patients have reduced levels of VEGF mRNA and 
protein in lung tissue.  It is unknown whether the decrease in VEGF is a cause or 
consequence of COPD although recent studies show the link between VEGF inhibition 
and emphysema [226].  Patients with RSV infection demonstrate high nasal 
concentrations of VEGF [227].  In vitro studies using A549 cells exhibit elaboration of 
VEGF by RSV infected cells, in contrast to rhinovirus which does not stimulate VEGF 
production [229].  The role of VEGF is largely unknown in many pulmonary disease but 
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altered levels appear to have an effect of function.  The next section will discuss VEGF 
as a therapeutic for pulmonary diseases.  
VEGF as a therapeutic compound 
 Given VEGF’s role in surfactant homeostasis and epithelial repair, the utilization 
of VEGF treatment has been investigated in several pulmonary disorders including 
respiratory distress syndrome (RDS), hyperoxic injury and pulmonary hypertension.  A 
study of respiratory distress in premature mice showed that intra-amniotic and 
intratracheal administration of VEGF increased surfactant protein synthesis, improved 
lung function and protected preterm mice against RDS without adverse side effects [216].  
In a study of neonatal hyperoxia, treatment with VEGF increased pulmonary edema early 
but improved lung structure during recovery, indicating a role in reparative processes 
[230].  VEGF treatment in a sheep model of pulmonary hypertension reduced the severity 
of pulmonary vascular remodeling and preserved vasodilation, thereby reducing 
hypertension [223].  The side effects of VEGF treatment in the RDS, hyperoxic injury 
and pulmonary hypertension model were none to minimal [216, 223, 230], however there 
are reports of severe side effects with higher concentrations of VEGF treatment.  
Transgenic neonatal mice overexpressing VEGF have pulmonary hemorrhage, 
hemosiderosis and airspace enlargement [231].  However, VEGF levels were much 
higher than physiologic levels in this study.  Numerous studies indicate that lower doses 
of VEGF are required to improve endothelial and epithelial cell functions with far fewer 
side effects [232, 233]. 
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Summary 
RSV animal models are vital to further understand RSV disease pathogenesis and 
to investigate therapeutic development.  The ovine model is ideal in that pulmonary 
development and structure are similar to that of human lung and RSV induced pulmonary 
pathology is similar to human RSV disease.  The pulmonary innate immune response is 
integral in protecting infants from severe RSV disease.  Treatment with vascular 
endothelial growth factor prior to RSV infection may act to enhance the innate immune 
response, provide epithelial protection, and promote epithelial repair processes. 
The specific goals of this dissertation were to: 
1.  describe and characterize the pulmonary pathology, antigen localization and 
epithelial innate responses in an ovine model of respiratory syncytial virus 
infection using a human RSV strain, strain A2.   
2. determine the effect of pulmonary administration of human recombinant 
VEGF prior to RSV infection on viral load, pulmonary pathology and 
epithelial innate immune responses in the characterized RSV model. 
3. determine the effect of ontogeny on the expression and localization of 
endogenous VEGF and VEGF receptors in the ovine lung. 
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CHAPTER 2. HUMAN RESPIRATORY SYNCYTIAL VIRUS A2 STRAIN 
REPLICATES AND INDUCES INNATE IMMUNE RESPONSES BY 
RESPIRATORY EPITHELIA OF NEONATAL LAMBS 
A paper published in International Journal of Experimental Pathology 
2009 Aug;90(4):431-8. 
Alicia Olivier, Jack Gallup, Marcia M.M.A. de Macedo,  
Steven M. Varga, Mark Ackermann 
Summary 
Human respiratory syncytial virus (RSV) is a pneumovirus that causes significant 
respiratory disease in pre-mature and full-term infants.  It was our hypothesis that a 
common strain of RSV, strain A2, would infect, cause pulmonary pathology, and alter 
respiratory epithelial innate immune responses in neonatal lambs similarly to RSV 
infection in human neonates.  Newborn lambs between 2 and 3 days of age were 
inoculated intrabronchially with RSV strain A2.  The lambs were sacrificed at days 3, 6, 
and 14 days post-inoculation.  Pulmonary lesions in the 6-day post-inoculation group 
were typical of RSV infection including bronchiolitis with neutrophils and mild 
peribronchiolar interstitial pneumonia.  RSV mRNA and antigen were detected by qPCR 
and immunohistochemistry respectively with peak mRNA levels and antigen at day 6.  
Expression of surfactant proteins A and D, sheep beta-defensin-1 and thyroid 
transcription factor 1 mRNA were also assessed by real-time qPCR.  There was a 
significant increase in surfactant A and D mRNA expression in RSV-infected animals at 
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day 6 post-inoculation.  There were no significant changes in sheep beta-defensin-1 and 
thyroid transcription factor-1 mRNA expression.  This study shows that neonatal lambs 
can be infected with RSV strain A2 and the pulmonary pathology mimics that of RSV 
infection in human infants thereby making the neonatal lamb a useful animal model to 
study disease pathogenesis and therapeutics.  RSV infection induces increased expression 
of surfactant proteins A and D in lambs, which may also be an important feature of 
infection in newborn infants. 
Introduction 
Respiratory syncytial virus (RSV) is a pneumovirus that causes severe respiratory 
disease in infants and recurrent upper airway tract infections in older children and adults.  
Approximately 75,000 to 125,000 hospitalizations in the United States are attributed to 
RSV induced bronchiolitis or pneumonia (Shay, et al., 1999).  Populations at increased 
risk for severe disease or death include premature infants, older adults and individuals 
with respiratory, cardiac or immune compromise (Murata and Falsey, 2007, Welliver, 
2003).  There are many factors both host related and environmental that appear to be 
involved in the increased risk for premature infants (Welliver, 2003).   
The innate immune system initiates the first line of defense against pathogens 
through phagocytosis and secretion of inflammatory and antimicrobial mediators.  
Epithelial and phagocytic cells produce and secrete antimicrobial peptides and surfactant 
proteins that complement and synergize with inflammatory and chemotactic mediators 
(Bals and Hiemstra, 2004).  Epithelial cells are especially integral as they are infected by 
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the virus which activates receptors such as retinoic acid-induced gene 1 (RIG-1) which 
induces epithelial cell activation. 
Lesions associated with human RSV infection include bronchiolitis, interstitial 
pneumonia and consolidation resulting in coughing and wheezing (Gilca, et al., 2006).  
Histologically, patients with RSV have bronchioles that are obstructed by mucous, fibrin 
and sloughed epithelial cells and neutrophils (Johnson, et al., 2007).  Previously our 
laboratory has shown that pre-term lambs infected with bovine respiratory syncytial virus 
(bRSV) develop clinical responses (coughing, temperature, increased respiratory rates) 
and lesions that parallel those of human disease.  We have also demonstrated a 
correlation between lamb age and disease susceptibility with more severe disease 
demonstrated in younger, pre-term lambs, which is similar to increased severity of RSV 
infection seen in human pre-term infants (Meyerholz, et al., 2004, Welliver, 2003).   
The pulmonary development and cellular composition of the neonatal lamb lung 
are similar to that of human infants.  Alveologenesis begins prenatally in both humans 
and lambs, in contrast to the postnatal alveolar development in mice and rodents 
(Flecknoe, et al., 2003, Langston, et al., 1984, Scheuermann, et al., 1988).  In addition, 
epithelial cells of the airways, distal bronchioles and alveoli in lambs are similar to those 
of humans, in comparison mouse lung has a large population of Clara cells in bronchiolar 
airways (Mariassy and Plopper, 1983, Pack, et al., 1981).  Sheep have been used to 
model a variety of human pulmonary diseases including asthma, pulmonary hypertension, 
cystic fibrosis, chronic obstructive pulmonary disease, congenital diaphragmatic hernia 
and numerous others (Abraham, 2008, Davey, et al., 2005, Scheerlinck, et al., 2008). 
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In this study, we hypothesized that a common strain of human RSV, strain A2, 
would infect neonatal lambs and cause pathology similar to human neonates.  In addition 
to characterizing the pulmonary pathology we examined the duration of infection to 
determine the time of peak viral lesions and time at which clearance was obtained.  We 
hypothesized that the virus would alter expression of respiratory epithelial innate immune 
genes known to have anti-RSV activity including surfactant proteins A (SP-A) and D 
(SP-D) and sheep beta-defensin-1 (SBD-1).  Expression of thyroid transcription factor-1 
(TTF-1), a key SP-A transcription factor, was also measured. 
Materials and methods 
Experimental Design 
Animal use and experimental procedures were approved by Iowa State University’s 
Animal Care and Use Committee.  Neonatal lambs (2-3 days of age) were randomly 
assigned to two groups, a control group (n=10) or RSV inoculated group (n=18).  Lambs 
were anesthetized with an intramuscular injection of xylazine (0.1 mg/kg), placed in right 
lateral recumbency and inoculated with human respiratory syncytial virus, strain A2 (5 
ml of 2x107 pfu/ml RSV) via fiberoptic bronchoscope in the right terminal bronchus 
followed by a sterile saline flush (10 ml).  Control animals were inoculated with cell 
growth media (5 ml) without the virus followed by a sterile saline flush (10 ml).  RSV 
(A2 strain) was a gift from Barney S. Graham (National Institutes of Health; NIH, 
Bethesda, MD) and was grown in HEp-2 cells (American Type Culture Collection; 
ATCC, Manassas, VA).  Lambs were given daily antibiotics (ceftiofur, 2.2 mg/kg, 
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intramuscular) to prevent bacterial complications.  Lambs were monitored for clinical 
signs of respiratory disease (coughing and wheezing) and daily temperatures were 
measured.  Animals were sacrificed by sodium pentobarbital on days 3 (control n=3, 
RSV n=6), 6 (control n=4, RSV n=6) and 14 post-inoculation (control n=3, RSV n=6).  
Tissue 
The thorax was opened and the lungs were examined for gross lesions.  The lungs were 
then removed for tissue collection.  In all animals, tissue samples were taken at the same 
location of the right cranial, middle and caudal lobes and left cranial lung lobe.  Samples 
were placed in cassettes and then in 10% neutral-buffered formalin for histological and 
immunohistochemical analysis. Additional samples were taken from these sites and snap-
frozen on dry ice for real-time quantitative PCR (Meyerholz, et al., 2004). 
One-step real-time qPCR 
Total RNA was isolated from whole lung tissue (affected areas as determined grossly or 
by immunohistochemistry for RSV antigen) via Trizol according to manufacturer’s 
guidelines (Invitrogen).  RNA samples were assessed by spectrophotometry and DNase 
treated (Ambion, TURBO DNase).  Real-time quantitative PCR (qPCR) was carried out 
as a fluorogenic one-step process in a GeneAmp 5700 Sequence Detection System 
(Applied Biosystems) using previously described methods.  Primer and probe sequences 
used in our laboratory have been previously described (Hu, et al., 2003, Kawashima, et 
al., 2006)(Table 1).  All samples were run in duplicate and each target gene amplification 
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was converted to a relative quantity and normalized to the geometric mean of two 
housekeeping genes, hRibo18S and ovRPS15 (Gallup and Ackermann, 2006). 
Histologic Examination  
The lung histologic lesion score was determined by the percentage of parenchymal 
consolidation of each section of lung and immunohistochemical antigen staining for 
RSV.  The scoring scale for the alveolar consolidation was; 0, no consolidation; 1, <30%; 
2, 30-60%; 3, >60%.  The scoring scale for the RSV antigen staining was; 0, no staining; 
1, 1-5 positive cells; 2, 6-10 positive cells; 3, >10 positive cells.  All evaluations were 
made based on the average of 10, 20X fields per section and 4 sections per lung per 
animal.  Group averages were calculated for the RSV antigen score and the alveolar 
consolidation score. 
Immunohistochemistry 
Immunohistochemistry for RSV antigen was performed on paraffin-embedded tissue as 
described previously (Meyerholz, et al., 2004).  Briefly, sections were cut at 5 µm 
thickness onto positively charged slides.  Following routine deparaffinization, sections 
were treated with Pronase E (Protease Type XIV from Streptomyces griseus, Sigma) for 
12 minutes at 37°C.  Nonspecific binding was blocked by incubation in 20% normal 
swine serum.  The sections were incubated with polyclonal goat anti-RSV antibody 
(BioDesign/Meridian) overnight at a concentration of 1:50 with 5% normal swine serum.  
The slides were rinsed and then incubated with biotinylated rabbit anti-goat secondary 
antibody (KPL) at a concentration of 1:300 in 5% normal sheep serum.  A peroxidase 
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block with 3% peroxide was followed by incubation with peroxidase-conjugated 
streptavidin (BioGenex) for 45 minutes.  After two PBS washes, the color was developed 
with Nova Red.  The slides were then counterstained with Harris’ hematoxylin, 
dehydrated and cover-slipped.  
Statistical analysis  
Data are expressed as means ± SEM.  For the temperature data, the group means on each 
day were analyzed for significance (RSV infected versus control) using unpaired student 
t-tests.  The histologic lesion score data was analyzed using the Wilcoxon-Mann-Whitney 
test.  The RT-qPCR data was LOG-transformed to stabilize variances across means and 
bring data to a normal distribution.  A two-way ANOVA (unbalanced design) was used 
to test for significant effects of treatments (control versus RSV infected), groups (3, 6, 
and 14 days post-inoculation time-points), and their interaction. A two-sample t-test was 
used to compare target genes expression at post-inoculation time-points.  The Pearson 
product-moment correlation coefficient was used to evaluate relationships between hRSV 
levels and expression of various target genes.   
Results 
Clinical and post-mortem findings   
RSV-infected lambs had significantly higher temperatures than control animals at 
days 1-6 post-inoculation (Figure 1, P < 0.05).   Clinically, 3 of the 6 lambs in the 6 day 
post-inoculation group developed a slight to moderate cough on days 4 and 5 post-
inoculation.  2 of the 6 lambs in the 14 day post-inoculation group developed a moderate 
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cough on day 5 post-inoculation with resolution of the cough at day 10.  At post-mortem 
examination gross lesions were characterized by multifocal to locally extensive reddened 
areas of pulmonary consolidation which varied in severity from moderate to severe.  In 
the 6-day post-inoculation group, 5 of the 6 infected animals had gross lesions.  No gross 
lesions were present in the 3 and 14-day post-inoculation group.   
Histology and immunohistochemistry 
Histologically, RSV induced changes were characterized by mild to moderate 
suppurative bronchiolitis with sloughed epithelial cells, cellular debris and neutrophils in 
the lumen of the medium to small airways at days 3 and 6.  Also present was a mild to 
moderate peribronchiolar mononuclear interstitial pneumonia containing lymphocytes 
and plasma cells and locally extensive areas of alveolar consolidation (Figure 2 A and B).  
In the 3-day post-inoculation group, all six lambs inoculated with RSV had histological 
changes consistent with RSV infection.  In the 6-day post-inoculation group, 5 of the 6 
RSV inoculated lambs had histological changes associated with RSV virus.  In the 14-day 
post-inoculation group, 3 of the 6 RSV inoculated lambs had minimal changes 
characterized by multifocal small areas of alveolar consolidation.   
Immunoreactivity for RSV antigen was present within the airway, bronchiolar 
epithelium and the syncytial cells in consolidated areas in the 3 and 6-day post-
inoculation groups (Figure 2 C and D).  Immunoreactivity to RSV antigen was not 
present in the 14-day post-inoculation group.  A histologic score was calculated for RSV 
immunoreactivity and alveolar consolidation for each group (Figure 3).  Animals in the 6 
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day RSV post-inoculation group had significantly higher scores for RSV 
immunoreactivity and alveolar consolidation as compared to the 3 day RSV post-
inoculation group (P < 0.05).  There was a significant decrease in both lesion scores in 
the 14 day RSV post-inoculation group (P <0.05).   
Epithelial innate immune gene expression 
Expression of RSV, SP-A, SP-D, SBD-1 and TTF-1 were measured by qPCR.  
The analysis showed significant increase in RSV mRNA from day 3 to day 6 post-
inoculation (P < 0.01) and a significant decrease from day 6 to 14 post-inoculation (P < 
0.01) (Figure 4).  The analysis showed statistically significant differences in SP-A and 
SP-D levels between infected and control groups.  There was a significant (P < 0.05) 
increase in expression of SP-A between RSV-infected and control animals in all three 
groups.  However, there was no significant difference in expression of SP-A in the RSV-
infected lambs between different post-inoculation time-points (Figure 5).  There was a 
significant increase in expression of SP-D between 3-day and 6-day post-inoculation 
animals and a significant decrease between 6-day and 14 days post-inoculated animals 
(Figure 6, P < 0.03).  There was a significant difference between control and infected 
animals in the 6-day post-inoculation group (P < 0.03).  In addition there was a 
correlation between RSV levels and SP-D expression in infected animals.  There were no 
significant differences in SBD-1 and TTF-1 expression between the infected and non-
infected groups. 
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Discussion 
Neonatal lambs infected with human respiratory syncytial virus (RSV), strain A2 
develop lesions consistent with those seen in human infant RSV infection (Johnson, et 
al., 2007, Welliver, et al., 2007).  Histologically, bronchiolitis was characterized by 
infiltration of neutrophils and macrophages into the bronchiolar lumen admixed with 
degenerate epithelial cells and cellular debris.   In addition, there were multifocal to 
locally extensive areas of alveolar consolidation with numerous syncytial cells and 
infiltrates of lymphocytes and plasma cells at days 6 and 14.  Pulmonary lesions are also 
similar to those that occur experimentally in lambs with bRSV and in natural spontaneous 
lesions of bRSV-infected cattle (Lehmkuhl and Cutlip, 1979).  Pulmonary pathology was 
most severe at 6 days post-inoculation at which time animals exhibited cough and high 
temperatures.  By 14 days post-inoculation, lambs had almost complete resolution given 
the lack of gross lesions, histologic changes and immunoreactivity for RSV antigen at 
this time point.  The infection and disease progression correlates to a previous study of 
experimental RSV infection in lambs in which infected lambs showed clinical signs 
associated with RSV infection, however, in that study tissue collection was carried out 
four weeks following inoculation, therefore no histological changes were present (Lapin, 
et al., 1993).    
The perinatal lamb has several key features consistent with human infant RSV 
infection and pulmonary development that make it a very good animal model.  As shown 
here, lambs develop histological lesions similar to human infection.  Robust RSV 
pathology is lacking in many rodent models of human RSV infection thereby making the 
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ovine model more attractive (Kong, et al., 2005).  These lesions represent a moderate 
human infection such that resolution is possible, which commonly occurs in infants.   The 
severity of pneumonia in this model can likely be enhanced by increasing the viral 
density and volume of viral inoculum. 
Associated with gross lesions were significant increases in expression of 
surfactant proteins A and D (Figures 5 and 6).  The increase in SP-A expression is similar 
to studies with lambs inoculated with bRSV and indicates a cellular response to the virus 
(Kawashima, et al., 2006).  Both SP-A and SP-D have anti-RSV activity which include 
viral opsonization and activation of macrophages, which are thought to play a critical role 
in RSV clearance (Hickling, et al., 2004, Sano and Kuroki, 2005).  In severe human RSV 
infection, SP-A protein levels are decreased (Kerr and Paton, 1999).  Our previous work 
has shown that paramyxoviral infection in sheep increases SP-A gene expression but does 
not significantly increase SP-A protein levels (Grubor, et al., 2004).  Human individuals 
with deleterious polymorphisms in the SP-A gene show increased severity of RSV 
infection − indicating the importance of SP-A in viral clearance and demonstrating the 
importance of this protein clinically (Lahti, et al., 2002).  Moreover, SP-D enhances RSV 
macrophage uptake and plays a role in modulating the immune response.  Mice deficient 
in SP-D exhibit impaired RSV clearance and an increased neutrophilic response and 
human SP-D polymorphisms are associated with either increased severity of RSV or 
protection against severe infection (Lahti, et al., 2002, LeVine, et al., 2004, Pastva, et al., 
2007). 
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Beta defensin expression in the lung is developmentally regulated in both humans 
and sheep (Meyerholz, et al., 2006, Starner, et al., 2003).  Beta defensins are produced by 
pulmonary epithelial cells and leukocytes and have antimicrobial properties (Hickling, et 
al., 2004, Schutte and McCray, 2002).  In this study, SBD-1 expression was not 
significantly altered by RSV infection.  In humans, HBD-1 is constitutively produced in 
the lung and is not inducible by pro-inflammatory mediators (Starner, et al., 2005).  This 
may be similar in the ovine and explain the lack of up-regulation of SBD-1, however, in 
previous studies, SBD-1 was up-regulated with parainfluenza virus (PIV-3) indicating 
that under certain conditions this gene may be inducible (Grubor, et al., 2004).   
Thyroid transcription factor-1 is a nuclear transcription factor that is most 
prevalent in the type II epithelial cells in the alveolus in the perinatal lung.  TTF-1 binds 
to regulatory promoter elements of surfactant protein A in addition to other surfactant 
proteins (DeFelice, et al., 2003).  TTF-1 mRNA levels did not increase during RSV 
infection despite the increases in SP-A mRNA levels.  This may indicate that other 
regulatory factors are involved or that the duration in which there is up-regulation of the 
transcription factor is at an earlier time-point prior to our sample collection (e.g. day 3).  
The regulation of surfactant protein expression is complex involving multiprotein 
signaling complexes.  TTF-1 interacts with many other transcription factors and co-
factors such as FOXa2, GATA-6, AP-1, C/EBPα, NFATc3 and retinoic acid receptors 
(Besnard, et al., 2007, Dave, et al., 2004).  It is also possible that SP-A up-regulation 
could be downstream to RIG-1 activation. 
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We have previously shown that pre-term lambs infected with bRSV have more 
severe RSV lesions than full-term lambs (Meyerholz, et al., 2004).  We expect that 
infection of pre-term lambs with this human strain of RSV would similarly have 
increased lesion severity similar to human premature infant disease.   
This study shows that the pulmonary pathology of RSV in neonatal lambs is 
similar to a moderate human infant RSV infection.  This is the first time that the 
pulmonary epithelial innate immune response has been characterized in the neonatal lamb 
model of human RSV.  In this study, RSV infection up-regulated surfactant proteins A 
and D expression but did not alter the expression of sheep beta-defensin-1 or thyroid 
transcription factor.  Future work in our laboratory using this model will elucidate other 
key roles of epithelial cells in RSV infection and allow a useful model for therapeutic 
trials. 
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6FAM or VIC, 5’ Fluorescent reporter dye; TAMRA, Fluorescent quencher dye; 
MGBNFQ, Minor groove binding  6FAM or VIC, 5’ Fluorescent reporter dye; TAMRA, 
Fluorescent quencher dye; MGBNFQ, Minor groove binding non-fluorescent quencher 
Table 1.  Primers and probe sequences for ovine gene expression assessed by real-time 
qPCR 
RSV Fwd: 5'-GCTCTTAGCAAAGTCAAGTTGAATGA 
 Rev: 5'-TGCTCCGTTGGATGGTGTATT 
 Probe: 5’-6FAM-ACACTCAACAAAGATCAACTTCTGTCATCCAGC-
TAMRA 
SP-A Fwd: 5'-TGACCCTTATGCTCCTCTGGAT  
 Rev: 5'-GGGCTTCCAAGACAAACTTCCT  
 Probe: 5'-6FAM-TGGCTTCTGGCCTCGAGTGCG-TAMRA 
SP-D Fwd: 5'-ACGTTCTGCAGCTGAGAAT  
 Rev: 5'-TCGGTCATGCTCAGGAAAGC  
 Probe: 5'-6FAM-TTGACTCAGCTGGCCACAGCCCAGAACA-TAMRA 
SBD1 Fwd: 5'-CCATAGGAATAAAGGCGTCTGTGT  
6 Rev: 5'-CGCGACAGGTGCCAATCT  
 Probe: 5'-6FAM-CCGAGCAGGTGCCCTAGACACATGA-TAMRA 
TTF-1 Fwd: 5'-TCCCAGGCGCAGGTGTAT 
 Rev: 5'-CGGACAGGTACTTCTGCTGCTT 
 Probe: 5’-6FAM-AGCTGGAGCGACGCT-MGBNFQ 
hRibo18S Fwd: 5’-CGGCTACCACATCCAAGGAA 
 Rev: 5’-GCTGGAATTACCGCGGCT 
 Probe: 5’-VIC-TGCTGGCACCAGACTTGCCCTC-TAMRA 
ovRiboProteinS15 Fwd: 5’-CGAGATGGTGGGCAGCAT 
 Rev: 5’-GCTTGATTTCCACCTGGTTGA 
 Probe: 5’-VIC-CCGGCGTCTACAACGGCAAGACC-TAMRA 
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Figures: 
Figure 1:  Average body temperatures by control and RSV infected lambs.  RSV infected 
lambs had significant increases in body temperature (*P < 0.05).  Values are expressed as 
means ± SD. 
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Figure 2:  A. Lung from a control lamb not infected with RSV that contains a bronchiole 
surrounded by non-collapsed alveoli with a central lumen.  B.  Lung from a lamb 6 days 
post-inoculation with RSV.  Within the lumen of the bronchiole (outlined) are sloughed 
epithelial cells mixed with degenerate neutrophils (*).  The alveoli surrounding the 
bronchiole are collapsed with accumulation of degenerate neutrophils and areas of necrosis 
(arrow). C and D.  Immunohistochemistry for RSV antigen on lung tissue from a lamb 6 
days post-inoculation with RSV, in which there is immunoreactivity within the bronchi, 
epithelial cells lining the bronchi, and the syncytial cells in areas of alveolar consolidation.  
Bars = 25 µm. 
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Figure 3:  Histologic lesion score based on RSV antigen staining and alveolar consolidation 
of RSV infected animals at 3, 6, and 14 days post-inoculation.  RSV antigen staining and 
alveolar consolidation scores were highest at day 6 post-inoculation.  Values are expressed as 
means ± SD.  +P < 0.05 vs other time points.   
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Figure 4:  Comparison of mRNA levels of RSV between groups.  There was a significant 
increase in the expression of viral mRNA between RSV infected vs control animals at 3 and 
6 days post-inoculation (*P < 0.01). There was a significant increase in expression of RSV 
between RSV infected animals at 6 days post-inoculation vs other time points (+P < 0.01).  
Control animals lack RSV mRNA.  Values are expressed as means ± SD. 
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Figure 5:  Comparison of mRNA levels of SP-A between groups.  There was a significant 
increase in expression of SP-A between RSV infected vs control animals (*P < 0.05) at all 
post-inoculation time points.  There was no significant difference in expression of SP-A in 
the RSV-infected lambs between different post-inoculation time-points.  Values are 
expressed as means ± SD. 
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Figure 6:  Comparison of mRNA levels of SP-D between groups.  There was a significant 
increase in expression of SP-D between RSV infected vs control animals at the 6-day post-
inoculation time point (*P < 0.03).  There was a significant increase in expression of SP-D 
between RSV infected animals at 6 days post-inoculation compared to other time points (+P 
< 0.03).  There was a correlation between RSV levels and SP-D expression in infected 
animals (r=0.60, P < 0.008).  Values are expressed as means ± SD. 
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CHAPTER 3. EXOGENOUS ADMINISTRATION OF  
VASCULAR ENDOTHELIAL GROWTH FACTOR PRIOR TO HUMAN 
RESPIRATORY SYNCYTIAL VIRUS A2 INFECTION REDUCES 
PULMONONARY PATHOLOGY AND ALTERS EPITHELIAL INNATE IMMUNE 
RESPONSES 
A paper accepted for publication in Experimental Lung Research (2010) 
Alicia K. Olivier, Jack M. Gallup, Albert van Geelen, Mark R. Ackermann 
Abstract 
Human respiratory syncytial virus (RSV) affects thousands of children every year.  Vascular 
endothelial growth factor (VEGF) is a regulator of vasculogenesis, pulmonary maturation 
and immunity.  In order to test the extent to which VEGF may alter RSV infection, four 
groups of lambs received either human recombinant VEGF (rhVEGF) or PBS pretreatment 
followed by inoculation with human RSV, strain A2 or sterile media.  Lambs in each group 
were sacrificed at 2, 4 and 6 days post-infection.  Expression of surfactant protein-A (SP-A), 
surfactant protein-D (SP-D), sheep beta-defensin-1 (SBD-1), tumor necrosis factor α (TNFα), 
IL-6, IL-8, interferon β and endogenous VEGF were measured to determine effect of 
rhVEGF pretreatment.  RSV lambs pretreated with rhVEGF had reduced viral mRNA and 
decreased pulmonary pathology at day 6.  Pretreatment with rhVEGF increased mRNA 
expression of SP-A, SBD-1, and TNFα with alteration of expression in RSV lambs. 
Endogenous VEGF mRNA levels were increased at day 2 regardless of pretreatment.  
Pretreatment with rhVEGF increased pulmonary cellular proliferation in RSV lambs at day 4 
post-infection.  Overall, these results suggest that pretreatment with rhVEGF protein may 
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have therapeutic potential to decrease RSV viral load, decrease pulmonary lesion severity 
and alter both epithelial innate immune responses and epithelial cell proliferation. 
INTRODUCTION 
Respiratory syncytial virus (RSV) is a pneumovirus in the paramyxoviridae family.  
RSV is the most significant cause of acute respiratory tract infection in infants [1].  
Thousands of children are affected by RSV every year with more severe infection in 
premature and respiratory compromised infants [2].  There are few effective treatments for 
RSV, however prophylactic administration of an anti-RSV monoclonal antibody has been 
effective in decreasing disease in high risk infants and children [3].  Until an effective 
vaccine is developed there is still a great need to find and develop other therapeutic targets to 
decrease virus induced pathology. 
Vascular endothelial growth factor (VEGF) is a potent endothelial cell growth factor, 
mitogen, and survival factor [4] that has well-known vascular permeability functions 
important in inflammation and wound healing [5, 6].  VEGF has numerous non-endothelial 
functions and is highly expressed in tissues with specialized epithelial barriers such as the 
lung and kidney [7].  In the lung, VEGF is expressed by alveolar type II cells, bronchiolar 
epithelial cells [8] and alveolar macrophages [9, 10].  Given the high pulmonary expression 
there is a vast array of research examining altered levels of VEGF in pulmonary homeostasis 
and disease.   
VEGF-A is a member of the vascular endothelial growth factor family which also 
includes VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor.  The gene 
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encoding VEGF-A is comprised of eight exons that are alternatively spliced to yield multiple 
protein isoforms with varying activities [6, 10].  The isoforms include VEGF121, VEGF145, 
VEGF165, VEGF189 and VEGF206.  VEGF165  is the predominant isoform and the most potent 
[11].  VEGF121 is freely diffusible while VEGF189 and VEGF206 are bound within the 
extracellular matrix.  VEGF165 is both diffusible and sequestered to the cell surface and 
extracellular matrix via its heparin binding moieties.  
During pulmonary development adequate levels of VEGF are critical for the proper 
formation of pulmonary capillaries.  Inactivation of the VEGF-A gene in lung epithelia of 
mice embryos results in almost complete absence of pulmonary capillaries with abnormal 
alveolar septae formation [12].  Treatment of rats with a VEGF receptor blocker (SU5416) 
leads to alveolar apoptosis and subsequent emphysema, demonstrating that VEGF is 
necessary for the maintenance of alveolar structure [13].  There is controversy and 
conflicting data concerning the role of altered VEGF expression in acute and chronic 
pulmonary disease.  Previous in vitro studies show that RSV induces increased VEGF 
expression [14, 15].  This does not appear to be the case for all respiratory viruses as 
infection with rhinovirus does not result in an increase in VEGF expression [16].  
We previously demonstrated that lambs inoculated with human RSV, strain A2 
developed lesions similar to those of human neonates [17, 18] with peak infection observed 
at 6 days post-infection [18].  Ovine lung is a good pulmonary model as the pulmonary 
structure and development are similar to human lung and sheep are susceptible to human 
strains of RSV.  In addition, the respiratory epithelia of the airways, bronchioles and alveoli 
in sheep are composed of similar ratios in cell types as humans, whereas mice have large 
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populations of Clara cells in the bronchiolar airway [19, 20].  Sheep have similar bronchiolar 
glands, airway capillaries and cough reflexes as humans [21]. 
In this study, we hypothesized that pretreatment with recombinant human (rh) VEGF 
prior to infection with human RSV, strain A2, would increase expression of important 
epithelial innate immune genes and thereby increase viral clearance and reduce pulmonary 
pathology.  Additionally, we proposed that transcription of endogenous VEGF and VEGF 
receptors in the lung would be altered by RSV infection.   
METHODS 
Experimental Procedure 
Animal use and experimental procedures were approved by Iowa State University’s 
Animal Care and Use Committee.  Neonatal lambs (2-3 days of age) were randomly assigned 
to 3 main groups; 2 day (n= 16), 4 day (n=16) and 6 day (n=24) based on length of infection 
period.  Within each of these groups, animals were then assigned to treatment groups (Table 
1).  All lambs were pretreated with recombinant human VEGF165 (30µg/kg) (Invitrogen or 
GenWay Biotech, Inc.) or phosphate-buffered saline (PBS).  Animals in the day 2 and 4 
groups were treated via intrabronchial administration while those in the day 6 group were 
treated via intratracheal administration.  Thirty minutes following pretreatment, animals were 
inoculated with human RSV virus (10 ml, 3 x 106 pfu/ml) or cell growth media (10 ml).  RSV 
(A2 strain) was propagated in HEp-2 cells (American Type Culture Collection; ATCC, 
Manassas, VA).  The inoculum was a cleared supernatant from infected cells that underwent 
a centrifugation step to remove cellular debris.  The virus was tittered via plaque assay on 
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VERO cells according to standard protocols.  Prior to and following inoculation, lambs were 
administered daily antibiotics (ceftiofur, 2.2 mg/kg, intramuscular) to prevent bacterial 
pulmonary complications.  Lambs were monitored daily for clinical signs of respiratory 
disease (coughing and wheezing) and temperatures were recorded.  Animals were sacrificed 
by sodium pentobarbital on days 2, 4 and 6 post-inoculation. 
Tissue samples were taken at the same location of the right and left cranial, middle, 
caudal lobes and accessory lobe.  Samples were placed in cassettes and then in 10% neutral-
buffered formalin in preparation for histologic analysis. Additional lung samples were taken 
from these sites and snap-frozen on dry ice for real-time quantitative PCR. 
Immunohistochemical analysis 
Immunohistochemical staining was performed for RSV antigen (1:50, overnight 
incubation, goat anti-human polyclonal antibody, BioDesign/Meridian) and for proliferating 
cells using an antibody against the Ki67 protein (1:100, overnight incubation, mouse anti-
human monoclonal antibody; Dako).  Briefly, paraffin-embedded lung sections were cut at 
5µm thickness onto positively charged slides.  Slides were incubated at 58°C for 25 minutes, 
deparaffinized in xylene, rehydrated in graded ethanol washes and washed in phosphate-
buffered saline (PBS).  For RSV immunohistochemistry, tissue sections were treated with 
Pronase E (Protease Type XIV from Streptomyces griseus, Sigma) for 12 minutes at 37°C.  
Nonspecific binding was blocked by incubation in 20% normal swine serum.  For Ki-67 
immunohistochemistry, tissue sections were boiled for 15 minutes in 0.01M citric acid (pH 
6.0).  Following overnight incubation with the primary antibodies the slides were rinsed and 
then incubated with an appropriate biotinylated secondary antibody at a concentration of 
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1:300.  A peroxidase block with 3% peroxide was followed by incubation with peroxidase-
conjugated streptavidin (BioGenex) for 45 minutes.  After three PBS washes, the color was 
developed with Nova Red.  The slides were then counterstained with Harris’ hematoxylin, 
dehydrated and cover-slipped.  
Histology scoring 
Histologic lesion scores were determined from two lung sections per RSV infected 
lamb in each pre-treatment group (e.g., VEGF vs. PBS).  Sections were scored by a 
pathologist blinded to the study groups to determine total alveolar consolidation and cellular 
infiltration.  Alveolar consolidation was defined by reduced expansion of alveolar lumen due 
to alveolar septal infiltration of neutrophils, lymphocytes, plasma cells, and type II cell 
hypertrophy along with intralumenal accumulation of neutrophils, macrophages and small 
amounts of cell debris.  A total of five 20X fields were examined per lung section and 
alveolar consolidation was scored as: 0, no consolidation; 1, 1-30% consolidation; 2, 30-50% 
consolidation, 3, 60-80% consolidation, 4, >80% consolidation.  Values were averaged per 
section and converted to a percentage value. 
Two lung sections from all animals were examined to determine the number of Ki-67 
immunoreactive cells.  A total of ten 20X fields were examined per lung section and values 
were averaged.  
One-Step Real-Time qPCR 
Total RNA was isolated from whole lung tissue (affected areas as determined grossly 
or by immunohistochemistry for RSV antigen) via Trizol according to manufacturer’s 
84 
 
 
guidelines (Invitrogen, Carlsbad, CA).  Following RNA isolation, the pellets were 
resuspended in 0.1mM EDTA, pH 6.75 and heated at 65°C for 5 min.  Samples were diluted 
1:50 and absorbance readings at 260 and 280nm were measured to determine RNA 
concentration and purity.  RNA samples were DNase treated (TURBO DNase, Ambion) and 
diluted 1:10 with nuclease-free water and RNAseOUT (Invitrogen) for one-step real-time 
qPCR.  Reactions were carried out using SuperScriptTM III Platinum® One-Step quantitative 
RT-PCR System with ROX kit (Invitrogen).  A test plate was run using a mixture of RNA 
samples serially diluted to determine the optimal dilution range for each target.  Primer and 
probe sequences used in our laboratory have been previously described [18, 22, 23] (Table 
2).  The ovine VEGF primers and probe detected ovine VEGF isoforms (VEGF120, VEGF164, 
VEGF187).  Following determination of the optimal dilution range for each target, samples 
and standards were run in duplicate [24]. Each target gene amplification was converted to a 
relative quantity using a target specific standard curve and then normalized to the reference 
gene, ubiquitin and OvRPS15 [25].  
Statistical Analysis 
Statistical analyses were performed with commercially available statistics software 
(GraphPad Prism, GraphPad Software).  Data was analyzed for normal distribution and log 
transformed when necessary.  Comparisons were done using one-way ANOVA followed by 
Tukey’s post-test analysis.  Histologic lesion score data was analyzed using a Student t-test.  
Data are represented as means (SEM).  P < 0.05 was considered to be significant unless 
otherwise noted. 
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RESULTS 
Clinical Data 
 Lambs infected with RSV had increased body temperatures at days 2 and 3 post-
infection regardless of pretreatment group (data not shown).  Lambs in both pretreatment 
groups (PBS and VEGF) exhibited a moderate cough at days 4 and 5 post-infection.  
Histology and Immunohistochemistry 
Histologic lesions of RSV infected lambs were characterized by multifocal 
bronchiolitis with locally extensive alveolar consolidation.  Within the lumen of bronchi and 
bronchioles were neutrophils and macrophages admixed with cellular debris.  Alveoli 
surrounding affected bronchi were collapsed and infiltrated by neutrophils with fewer 
lymphocytes and plasma cells (Figure 1A).  Syncytial cells were present multifocally within 
bronchiolar epithelium and within consolidated alveolar parenchyma in lung tissue from PBS 
and VEGF pretreated lambs.  RSV antigen was detected in bronchiolar epithelial cells, 
syncytial cells and alveolar macrophages by immunohistochemistry (Figure 1B).  
Immunoreactive cells had intense, dark brown, cytoplasmic staining.  At day 6 post-infection, 
RSV infected lambs pretreated with rhVEGF had decreased alveolar consolidation, 
bronchiolitis and inflammatory cell infiltration as compared to RSV infected lambs 
pretreated with control media (Figure 1C).  There was reduced RSV antigen at day 6 post-
infection in rhVEGF pretreated lambs (Figure 1D).  Histologic lesion scores were calculated 
for each treatment group based on alveolar consolidation and inflammatory cell infiltration 
(Figure 2).     
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Real-time qPCR 
Effect of rhVEGF on RSV mRNA expression 
RSV mRNA levels were measured by RT-PCR to determine the effect of rhVEGF 
pretreatment on RSV replication.  Lambs pretreated with rhVEGF had significantly higher 
RSV mRNA levels at day 2 post-infection than RSV infected lambs pretreated with PBS.  
However at day 6, lambs pretreated with rhVEGF had a marked decrease in RSV mRNA 
levels as compared to lambs pretreated with PBS (Figure 3). 
Effect of RSV infection and rhVEGF administration on collectin and defensin gene 
expression 
Surfactant protein and defensins serve important roles in the pulmonary innate 
immune response.  Expression of SP-A, SP-D and SBD-1 mRNA were measured in order to 
determine the effect of rhVEGF pretreatment on the expression of these genes during RSV 
infection.  rhVEGF induced the expression of SP-A in non-RSV infected lambs pretreated 
with VEGF at day 4 and 6, indicating increased expression was a direct result of rhVEGF 
administration (Figure 4).  RSV infection induced expression of SP-A at day 4 in both 
pretreatment groups.  At day 6, RSV infected lambs pretreated with rhVEGF showed a 
marked reduction in SP-A expression compared with lambs pretreated with PBS at the same 
time point and expression at day 4.  There were no significant changes in SP-D expression 
between the groups.  
Administration of rhVEGF induced significant increase of SBD-1 mRNA in 
uninfected lambs at day 4 and 6, indicating increased expression was a direct result of 
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rhVEGF (Figure 5).  RSV infection induced expression of SBD-1 at days 2 and 4 post-
infection in both pretreatment groups, showing that increased expression was a result of viral 
infection.  At day 6, RSV infected lambs pretreated with rhVEGF had less SBD-1 expression 
than lambs pretreated with PBS and lower levels than those present at day 4. 
Effect of RSV infection and rhVEGF administration on inflammatory mediators 
 RSV infection induced the expression of TNFα and IL-8 at day 2 post-infection in 
both pretreatment groups (Figures 6, 7).  Administration of rhVEGF increased TNFα 
expression at day 4 (Figure 6).  There was no significant alteration in expression of IL-6 and 
IFNβ by RSV infection or rhVEGF administration.   
Alterations in endogenous VEGF expression due to RSV infection 
Expression of VEGF and VEGF receptors-1 and -2 by lung cells was measured to 
determine whether RSV infection and/or the administration of rhVEGF protein altered 
transcription of endogenous VEGF and cellular regulation of VEGF receptors-1 and -2.  
VEGF mRNA was significantly increased in RSV infected lambs at day 2 in both 
pretreatment groups (Figure 8).  However, at day 6, levels of VEGF mRNA were markedly 
decreased in both pretreatment groups. VEGF receptor transcription was not altered by viral 
infection or administration of rhVEGF (data not shown). 
Effect of RSV infection and rhVEGF administration on pulmonary cellular proliferation  
VEGF can reduce apoptosis of both endothelial cells and pulmonary epithelial cells 
[13, 26].  The effect of VEGF on the growth and proliferation of lung epithelial cells 
following injury is not well known.  To test this, cellular proliferation was measured within 
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the lung parenchyma by immunohistochemistry for Ki-67 antigen (Figure 9).  
Immunoreactive cells had intense, dark brown, nuclear staining.  Immunoreactive cells were 
present within bronchiolar epithelium and multifocally within the alveolar interstitium.  At 
day 4, RSV infected lambs pretreated with rhVEGF had increased cellular proliferation 
compared to control (Figure 10).  There was no significant difference in RSV infected lambs 
pretreated with PBS at this time point compared to PBS control.  At day 6, there were 
significantly more Ki-67 immunoreactive cells in RSV infected lambs pretreated with PBS 
compared to lambs pretreated with VEGF.  In fact, RSV infected lambs pretreated with 
rhVEGF had no increase in cellular proliferation over control at day 6. 
DISCUSSION 
VEGF has a vital role in pulmonary development, homeostasis and disease processes.  
This study demonstrates that administration of exogenous rhVEGF prior to RSV infection 
decreases the severity of RSV induced pulmonary lesions at day 6 post-infection.  In 
addition, viral load at 6 days post-infection was decreased in lambs pretreated with rhVEGF.  
Demonstration of rhVEGF-induced protection against RSV is consistent with our previous 
work demonstrating pulmonary protection with a bovine strain of RSV [27].  The 
mechanistic basis for decreased RSV pathology is largely unknown, however we propose 
that rhVEGF increases innate immune gene expression by pulmonary epithelial cells and 
promotes epithelial cell proliferation leading to enhanced cellular repair.  VEGF has 
numerous other pulmonary effects that may contribute to alteration of RSV disease including 
vascular leakage and macrophage activation.  An unexpected finding was an increase in RSV 
mRNA at day 4 post-infection in rhVEGF pretreated lambs.  The cause for the higher 
expression is unknown but may be related to alteration in cellular responses by rhVEGF.  
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There was no histologic evidence of increased cellular infiltration or pulmonary pathology 
that would indicate increased RSV disease at this time point. 
SP-A is a collectin that plays a critical role in pulmonary innate immune responses and 
also modulates inflammatory responses.  SP-A acts as an opsonin by binding and 
agglutinating pathogens and also serves to modulate inflammatory responses in the lung [28].  
Exogenous pulmonary VEGF administration increases SP-A expression and expression of 
other surfactant proteins, resulting in pulmonary maturation and making VEGF a possible 
therapeutic for pulmonary immaturity [29, 30].  Other routes of VEGF administration also 
increase pulmonary surfactant expression.  In a preterm rat study, rats given VEGF via intra-
amniotic administration resulted in increased expression of SP-B and SP-D [31].  SP-A has 
important anti-viral functions including direct virus binding and immune modulation [32].  
Human infants with polymorphisms in the SP-A gene show increased susceptibility to RSV 
infection [33].  Studies using SP-D knockout mice demonstrate that RSV infection results in 
impaired viral clearance with increased infiltration of neutrophils [34].  In this study, lambs 
pretreated with rhVEGF had markedly increased SP-A expression, similar to other studies 
using exogenous rhVEGF administration.  Lambs infected with RSV alone had increased 
expression of SP-A, corresponding to previous studies showing that RSV induces SP-A 
expression [18].  Interestingly at day 6 post-infection, SP-A expression in RSV infected 
lambs pretreated with rhVEGF was much lower than animals pretreated with PBS and also 
decreased from day 4.  Although rhVEGF induces expression of SP-A there appears to be 
modulation of this effect when lambs are infected with RSV.  Reduced expression of SP-A at 
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day 6 in RSV infected lambs pretreated with VEGF may be secondary to the effects of the 
rhVEGF, which may decrease viral load and result in less viral induction of SP-A.   
Beta defensins are antimicrobial peptides that have important roles in both the innate and 
adaptive immune responses.  The antiviral activity of β-defensins include direct anti-viral 
activity, chemotactic activity for macrophages and immature dendritic cells, and induction of 
cytokine signaling by monocytes and epithelial cells [35].  RSV infection induced expression 
of SBD-1 at 2 and 4 days in both pretreatment groups.  Pretreatment with rhVEGF in non-
RSV infected lambs induced expression of SBD-1 at days 4 and 6.  The induction of SBD-1 
expression by VEGF has been documented in a previous study showing that VEGF 
modulates components of the innate immune response [27].  At day 6, SBD-1 levels in RSV 
infected lambs pretreated with VEGF were much lower than lambs pretreated with PBS.  The 
lower expression level in this group is similar to the decreased expression observed with SP-
A.  Again, the cause for the lower expression in this group is unknown, but may be related to 
a decrease in viral-induced epithelial responses. 
A study investigating VEGF levels in human infants with RSV infection showed up-
regulation of VEGF in the nasal fluid [36].  In many human studies nasal fluid and 
bronchoalveolar lavage (BAL) are the only means of measurement, as tissue samples are 
often difficult to obtain.  In this study, endogenous VEGF expression was increased at day 2 
but decreased at day 6.  VEGF mRNA was measured in lung homogenates, which may give 
an indication of the overall effect of RSV-induced inflammation on VEGF expression.  
VEGF is secreted both basolaterally and apically by pulmonary epithelial cells.  In addition, 
VEGF189 and VEGF206 are bound to the extracellular matrix within the lung tissue and 
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cleaved to active fragments by plasmin upon extracellular matrix breakdown [4].  Nasal 
secretion and BAL measurements provide information as to the expression level in one 
location only.  An example of the location differences in VEGF levels can be shown in a 
study using a neonatal pig lung injury model, which reported decreased VEGF mRNA 
expression and protein levels in lung tissue with increased protein levels in the BAL [37].  
This poses the question as to the significance of altered expression at various locations and 
time points in infection. 
Many pulmonary disease processes can result in or be caused by alterations in VEGF 
expression.  Decreased pulmonary VEGF expression is present in newborns with 
bronchopulmonary dysplasia and in acute respiratory distress syndrome [38, 39].  In one 
murine model of LPS-induced lung, VEGF mRNA and protein expression were increased 
following injury with evidence of pulmonary edema [40].  However, in a different model of 
acute lung injury induced by Pseudomonas aeruginosa, VEGF mRNA and protein were 
decreased [41].  In the injury model induced by Pseudomonas, direct injury to the epithelium 
may have resulted in decreased expression, although decreased levels may be an epithelial 
response to injury.  The fact that RSV infected lambs in both pretreatment groups showed 
similar VEGF mRNA expression may indicate a modulation of epithelial responses rather 
than epithelial loss leading to decreased expression. 
There is growing evidence that VEGF plays a supportive role in disease processes 
and that certain levels are necessary for cellular proliferation and differentiation.  In vitro 
studies indicate that VEGF has a positive effect on epithelial cellular proliferation and can 
increase cell survival via reduction of caspase-3 in apoptosis [42, 43].  At day 4 post-
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infection there was enhanced cellular proliferation in RSV infected lambs pretreated with 
rhVEGF.  Interestingly, by day 6 proliferation markedly decreased in this group.  We 
proposed that an increase in cellular proliferation in RSV infected lambs pretreated with 
rhVEGF would lead to enhanced lesion resolution.  We initially saw an increase in 
proliferation at day 4 but not at day 6.  However, lambs pretreated with VEGF had a marked 
decrease in pulmonary pathology at day 6 indicating that repair may have occurred at an 
earlier time point as may be suggested by the higher proliferation at day 4.  At day 6, RSV 
infected lambs pretreated with PBS had high cellular proliferation, likely due to the severity 
of RSV infection and the response to repair the injury.   
Intrapulmonary treatment with rhVEGF at the concentration used in this study 
resulted in minimal pulmonary pathology.  Administration of rhVEGF has been reported to 
cause mild increase in monocyte recruitment early after administration [44].  In a preterm 
mouse model of lung prematurity, intratracheal administration of rhVEGF resulted in 
increased surfactant protein production with no adverse effects on the lungs [29].  There is a 
report of pulmonary hemorrhage and hemosiderosis in a mouse model over-expressing 
VEGF; however VEGF protein was far higher than physiologic levels [45].  The lack of 
major adverse side effects with intrapulmonary administration makes VEGF a possible 
therapeutic candidate. 
The effect of rhVEGF pretreatment on viral infection is likely multi-factorial with 
effects on cellular proliferation and alteration of epithelial gene expression as described for 
SP-A and SBD-1.  In addition, VEGF is a monocyte/macrophage chemoattractant [44, 46] 
via VEGF R-1.  Macrophages not only internalize cellular debris but also modulate immune 
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responses in the lung by secretion of cytokines that are important for activation of CD8+ 
lymphocytes and antiviral responses [47].  Recruitment of macrophages may aid in the 
decreased lesions and virus that were observed in animals pretreated with rhVEGF.  A recent 
study demonstrated that VEGF serves an immunostimulatory role by increasing the 
expression of IL-8, TNFα, and IFNγ within 24 hours of administration [48].  In our study, 
VEGF increased TNFα with no effect on IL-6 and IL-8.   
This study shows that pretreatment with rhVEGF prior to RSV infection decreased viral 
mRNA and decreased pulmonary lesion severity at peak infection (day 6) as compared to 
RSV animals that did not receive rhVEGF.  In addition, rhVEGF increased SP-A and SBD-1 
expression exhibiting regulation of key epithelial innate immune genes. Pretreatment with 
rhVEGF altered cellular proliferation in RSV infected lambs at 4 and 6 days post-infection.  
There are likely other pulmonary effects induced by administration of rhVEGF in addition to 
those investigated here, that may provide interesting insight into disease pathogenesis and 
further the development of novel therapeutics.  
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Tables: 
Table 1:  Treatment groups for assessing VEGF pretreatment in RSV disease  
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pretreatment Inoculation 
n=4 (days 2, 4) n=6 (day 6) PBS  Media 
n=4 (days 2, 4) n=6 (day 6) PBS RSV 
n=4 (days 2, 4) n=6 (day 6) VEGF Media 
n=4 (days 2, 4) n=6 (day 6) VEGF RSV 
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Table 2.  Primers and probe sequences for ovine gene expression assessed by real-time 
qPCR 
6FAM or VIC, 5’ Fluorescent reporter dye; TAMRA, Fluorescent quencher dye; MGBNFQ, 
Minor groove binding non-fluorescent quencher 
RSV Fwd: 5'-GCTCTTAGCAAAGTCAAGTTGAATGA 
 Rev: 5'-TGCTCCGTTGGATGGTGTATT 
 Probe: 5’-6FAM-ACACTCAACAAAGATCAACTTCTGTCATCCAGC-
TAMRA 
SP-A Fwd: 5'-TGACCCTTATGCTCCTCTGGAT  
 Rev: 5'-GGGCTTCCAAGACAAACTTCCT  
 Probe: 5'-6FAM-TGGCTTCTGGCCTCGAGTGCG-TAMRA 
SP-D Fwd: 5'-ACGTTCTGCAGCTGAGAAT  
 Rev: 5'-TCGGTCATGCTCAGGAAAGC  
 Probe: 5'-6FAM-TTGACTCAGCTGGCCACAGCCCAGAACA-TAMRA 
SBD1 Fwd: 5'-CCATAGGAATAAAGGCGTCTGTGT  
 Rev: 5'-CGCGACAGGTGCCAATCT  
 Probe: 5'-6FAM-CCGAGCAGGTGCCCTAGACACATGA-TAMRA 
IL-8 
 
 
IL-6 
 
 
Tumor necrosis 
factor α 
 
 
Interferon β 
 
Fwd: 
Rev: 
Probe: 
Fwd: 
Rev: 
Probe: 
Fwd: 
Rev: 
Probe: 
Fwd: 
Rev: 
Probe: 
5'-TTCCAAGCTGGCTGTTGCT 
5'-TTGACAGAACTGCAGCTTCACA 
5'-6FAM-CCGCTTTCCTGCTCTCTGCAGCTC-TAMRA 
5'-GCTGCTCCTGGTGATGACTTC 
5'-GGTGGTGTCATTTTTGAAATCTTCT 
5'-6FAM-CTTTCCCTACCCCGGGTCCCCTG-MBGNFQ 
5'-CAACCTGGGACACCCAGAAT 
5'-TCTCAAGGAACGTTGCGAAGT 
5'-6FAM-CAAGGGCCAGGGTTCTTACCGGAA-TAMRA 
5'-TGGTTCTCCTGCTGTGTTTCTC 
5'-CGTTGTTGGAATCGAAGCAA 
5'-6FAM-ACCACAGCTCTTTCCAGGAGCTACA-TAMRA 
VEGF Fwd: 5'-GCCCACTGAGGAGTTCAACATC 
 Rev: 5'-TGGCTTTGGTGAGGTTTGATC 
 Probe: 5'-6FAMCCATGCAGATTATG-MGBNFQ 
VEGF Receptor-1 Fwd: 5’-TCAGGTGAGCTTGGACAAAATG 
 Rev: 5’-CACCGTGCAAGACAGCTTCA 
 Probe: 5'-6FAM-CTGCGGAAGGAGAG -MGBNFQ 
VEGF Receptor-2 Fwd: 5’-CCAGTGGGCTGATGACCAA 
 Rev: 5’-GCAACAAACGGCTTTTCATGT 
 Probe: 5'-6FAM-AAGAACAGCACGTTCGTCCGGG-TAMRA 
Ubiquitin Fwd: 5'-GGTGGCTGTTAATTCTTCAG 
 Rev: 5'-AAATGGCTAGAGTGCAGAACGAT 
 
OvRPS15 
Probe: 
Fwd: 
Rev: 
Probe: 
5'-6FAM-TTCATAATGCTCAGTGATGG-MGBNFQ 
5’-CGAGATGGTGGGCAGCAT 
5’-GCTTGATTTCCACCTGGTTGA 
5’-VIC-CCGGCGTCTACAACGGCAAGACC-TAMRA 
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Figures 
 
 
Figure 1:  Photomicrograph of lung from an RSV infected lamb pretreated with PBS (A) and 
RSV infected lamb pretreated with VEGF (C).  RSV infected lambs pretreated with PBS had 
suppurative bronchiolitis with locally extensive alveolar consolidation and infiltration of 
lymphocytes and plasma cells.  RSV infected lambs pretreated with VEGF had decreased 
alveolar consolidation, bronchiolitis and inflammatory cell infiltration.  RSV antigen staining 
by immunohistochemistry demonstrated multifocal immunoreactive cells within the 
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bronchiolar epithelium, airway lumen and interstitium (B).  Lambs pretreated with VEGF 
had decreased antigen at day 6 post-infection (D).  Bar =100µm 
 
 
 
Figure 2:  Pretreatment with exogenous rhVEGF decreased histologic consolidation score 
indicating a decrease in alveolar consolidation and inflammatory cell infiltration (*p<0.05). 
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Figure 3:  At day 2, lambs pretreated with rhVEGF had significantly higher RSV mRNA 
levels (A).  At day 4, RSV mRNA levels in the rhVEGF pretreated lambs were decreasing 
(B) with RSV mRNA expression levels significantly lower than PBS pretreated lambs at 6 
days post-infection (C) (*p<0.05, **p<0.01). 
 
 
 
 
 
RSV 
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Figure 4:  Pretreatment with exogenous rhVEGF and inoculation with RSV altered 
expression of surfactant protein A.  At day 4, administration of rhVEGF increased SP-A 
expression in non-RSV infected lambs, as compared to PBS pretreatment.  Inoculation with 
RSV increased SP-A in both control and rhVEGF pretreated groups (B).  At day 6, SP-A 
expression in rhVEGF pretreated non-RSV infected lambs remained increased.  SP-A 
expression was decreased in RSV infected lambs that were pretreated with rhVEGF 
compared to those that were pretreated with PBS (C) (*p<0.05, **p<0.01, ***p<0.001). 
 
SP-A 
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Figure 5:  Pretreatment with exogenous rhVEGF and inoculation with RSV altered 
expression levels of sheep beta-defensin-1 (SBD-1).  At day 2, inoculation with RSV 
increased SBD-1 levels in both pretreatment groups however SBD-1 expression was higher 
in animals pretreated with rhVEGF (A).  At day 4, administration of rhVEGF increased 
SBD-1 expression in non-RSV infected lambs, as compared to PBS control.  SBD-1 
expression in RSV infected animals remained increased (B).  At day 6, SBD-1 expression in 
RSV infected lambs pretreated with rhVEGF was significantly decreased compared to RSV 
infected lambs pretreated with PBS.  SBD-1 expression remained high in non-RSV infected 
lambs pretreated with rhVEGF (C) (*p<0.05, **p<0.01, ***p<0.001). 
SBD-1 
107 
 
 
 
 
 
Figure 6:  Pretreatment with exogenous rhVEGF and inoculation with RSV altered 
expression levels of TNFα.  At day 2, TNFα expression was significantly increased in RSV 
infected lambs in both pretreatment groups (A).  At day 4, TNFα expression increased in 
non-RSV lambs pretreated with rhVEGF.  Expression decreased from day 2 levels in RSV 
infected lambs with higher expression in lambs pretreated with rhVEGF (B) (*p<0.05, 
**p<0.01, ***p<0.001). 
 
 
 
 
 
TNFα 
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Figure 7:  RSV infection increased expression of IL-8 in both pretreatment groups (*p<0.05). 
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Figure 8:  At day 4, VEGF expression levels are increased in RSV infected lambs in both 
pretreatment groups.  At day 6, VEGF expression levels are decreased in RSV infected 
animals in both pretreatment groups (*p<0.05, ***p<0.001). 
VEGF 
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Figure 9:  Photomicrograph of immunohistochemical staining for Ki-67 antigen staining to 
measure cellular proliferation.  Immunoreactive cells are present multifocally within the 
bronchiolar epithelium and within the interstitium (A,B).  Bar =100µm 
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Figure 10:  Quantification of Ki-67 immunoreactive cells within lung tissue from lambs in 
all groups.  At day 4, RSV infected lambs pretreated with VEGF had increased numbers of 
Ki-67 immunoreactive cells compared to VEGF control.  At day 6, RSV lambs pretreated 
with PBS had increased number of KI-67 immunoreactive cells compared to PBS control  
RSV infected lambs pretreated with rhVEGF had no significant increase in Ki-67 
immunoreactivity (*p<0.05, ***p<0.001). 
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CHAPTER 4:  DIFFERENTIAL EXPRESSION OF VEGF ISOFORMS AND VEGF 
RECEPTORS DURING ONTOGENY OF OVINE LUNG 
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Abstract 
Vascular endothelial growth factor (VEGF) is a mediator of angiogenesis with multiple 
functions in lung development and homeostasis.  The purpose of this study was to define 
developmental expression of VEGF-A and its receptors in ovine lung.  VEGF mRNA and 
protein expression was measured in lung tissue from prenatal (115 and 130 days gestation), 
term, postnatal (15 days post-birth) and adult sheep.  Isoform-specific expression (VEGF120, 
VEGF164, VEGF188 and VEGF120b) was measured by reverse transcriptase PCR to determine 
if developmental patterns were present.  VEGF mRNA was most abundant at 115 and 130 
days gestation with low expression at term and in adult lung.  VEGF mRNA expression at 15 
days post-birth was similar to prenatal expression levels.  During prenatal development, 
angiogenic isoforms were highly expressed (VEGF120, VEGF164, and VEGF188) and 
significantly decreased at term.  VEGF receptor-1 was highly expressed early in development 
with decreased expression at term and 15 days post-birth.  VEGF receptor-2 was highly 
expressed at 15 days post-birth.  VEGF protein levels were low in prenatal lung but high in 
adult lung, which did not correlate to mRNA expression.  VEGF120b was the only anti-
angiogenic isoform detected by western blot indicating a possible role in development.  
113 
 
 
These results show that VEGF and VEGF receptors are differentially expressed during ovine 
pulmonary development and that mRNA levels do not correlate with protein expression.  
Introduction 
Vascular endothelial growth factor (VEGF) is a well-known endothelial cell mitogen 
that regulates endothelial cell differentiation in physiologic and pathologic angiogenesis.  
VEGF is also a potent mediator of permeability important in inflammatory processes (13).  
VEGF has additional non-endothelial functions, such as epithelial cell proliferation and 
macrophage activation.  In adults, VEGF is expressed in almost every tissue which 
underscores its vital nature (23).   
Expression of VEGF and VEGF receptors is present in bronchiolar epithelial cells, 
type II epithelial cells and alveolar macrophages (4, 6, 16, 24).  Studies demonstrate that 
pulmonary VEGF is important for the survival and growth of both endothelial and epithelial 
cells (37).  Decreased VEGF or VEGF receptor signaling in the lung leads to caspase-3 
dependent apoptosis of septal endothelial and epithelial cells resulting in emphysematous 
change (21, 34).  VEGF also functions in surfactant homeostasis and can upregulate 
surfactant protein production (11).   
The VEGF family consists of five members, VEGF-A, -B, -C, -D and placental 
growth factor.  VEGF-A is the most widely studied.  The VEGF-A (VEGF) gene is 
organized into eight exons that are alternatively spliced to form different polypeptide 
isoforms (16).  There are two families of VEGF isoforms, the pro-angiogenic isoforms 
(VEGFxxx) formed by proximal splice site selection in the terminal exon (exon 8) and the 
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anti-angiogenic isoforms (VEGFxxxb) generated by an alternate distal splice site, which 
results in a six amino acid difference at the carboxyl terminus (28).  For every angiogenic 
isoform there appears to be an inhibitory isoform that functions in modulating angiogenic 
functions.  VEGF121, 165 and 189 are the three main pro-angiogenic isoforms in humans.  Less 
frequently reported isoforms include VEGF145 (30), VEGF162 (22), and VEGF183 (20).  Mouse 
VEGF-A isoforms have one less amino acid than the human isoforms (VEGF120, VEGF164, 
VEGF188) (33) with sheep isoforms similar to those (VEGF120, 164, and 187) (A. van Geelen, 
unpublished observation).  VEGF isoforms have different receptor binding properties and 
location within the extracellular matrix (ECM).  VEGF189 binds heparin with high affinity 
and is therefore sequestered within the ECM.  VEG121 does not bind heparin and is a freely 
diffusible protein.  VEGF165 has intermediate binding properties and is both diffusible and 
bound to an extent to the cell surface and ECM (14).  The functions of the anti-angiogenic 
isoforms (VEGFxxxb) have not been completely characterized.  High expression of anti-
angiogenic isoforms have been found in non-angiogenic tissues such as the colon (36) and 
vitreous humor of the eye (29) with decreased expression in angiogenic conditions (28).  A 
recent study examined expression of VEGFxxxb in normal human adult lung and lung from 
patients with acute respiratory distress syndrome (ARDS) (35).  This study found significant 
VEGFxxxb protein expression in normal lung, primarily in alveolar epithelial cells and 
macrophages, with minimal expression in ARDS lung.  This study indicates that VEGFxxxb 
isoforms are significantly expressed in normal lung and likely have important homeostatic 
functions. 
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Expression of VEGF and VEGF receptors are critical to embryonic development.  
Deletion of a single VEGF allele (8, 15) or either of the VEGF receptors -1 (Flt-1) or -2 (Flk-
1) (16), results in embryonic lethality.  Mice expressing only VEGF120 survive to term but die 
soon after birth with vascular defects and altered endothelial cell distribution (9, 32).  
Embryonic over-expression of VEGF is also embryonic lethal, resulting in severe cardiac 
vascular abnormalities (25).   
In this study we measured the expression of VEGF mRNA and protein during lung 
development and in adult lung.  Expression was measured in prenatal (115 and 130 days 
gestation), term, postnatal (15 days post-birth) and adult lung.  Isoform-specific expression 
(VEGF120, VEGF164, VEGF188 and VEGF120b) was also measured to determine if isoform 
expression patterns were present during various stages of pulmonary development. 
Materials and Methods 
Tissue Collection: 
Tissues used in this study were stored from previous studies.  Lung tissue was 
collected from four fetuses at 115 days gestation (145 days is term), four fetuses at 130 days 
gestation, four term neonates (6 hours following natural birth), four lambs at 15 days post-
birth and four adults (>3 years of age).  Samples were collected and placed in cassettes then 
in 10% neutral-buffered formalin for immunohistochemical analysis.  Additional lung 
samples were snap-frozen on dry ice for PCR assays.  All procedures and protocols were 
reviewed and approved by the Animal Care and Use Committee at Iowa State University.   
VEGF Immunohistochemistry: 
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Immunohistochemical staining was performed for VEGF antigen (clone C-1, 200 
µg/ml used at 1:200) (Santa Cruz Biotechnology, Santa Cruz, CA).  Paraffin-embedded lung 
sections were cut at 5 μm thickness onto positively charged slides.  Slides were incubated at 
58°C for 25 minutes, deparaffinized in xylene, rehydrated in graded ethanol washes and 
washed in phosphate-buffered saline (PBS).  Antigen retrieval was performed in TRIS/EDTA 
(pH 9.0) for 15 minutes in a steamer, then cooled for 20 minutes to room temperature.  Slides 
were then rinsed with phosphate-buffered saline (PBS).  Nonspecific binding was blocked by 
incubation in 10% normal goat serum in TRIS/PBS with 3% bovine serum albumin (BSA).  
Following overnight incubation with the primary antibody (in TRIS/PBS/BSA) the slides 
were rinsed then incubated with a biotinylated anti-mouse antibody (KPL, Gaithersburg, 
MD) at a dilution of 1:200.  To control for nonspecific staining, a control slide was processed 
with omission of the primary antibody.  Following the secondary antibody, the slides were 
incubated for 20 minutes in a 3% peroxidase block then incubated with a peroxidase-
conjugated streptavidin (1:200) for 45 minutes (Invitrogen, Carlsbad, CA).  After three PBS 
washes, the color was developed with Nova Red (Vector).  The slides were then 
counterstained with Harris’ hematoxylin, dehydrated and cover-slipped.   
Immunohistochemisty scores were based on percent epithelial cell staining within 
bronchioles and staining intensity.  The percent of epithelial cells staining in bronchi was 
graded as follows: 1, 0-25%; 2, 25%-50%; 3, 50%-75%; and 4, 75%-100% from 10, 20X 
fields.  Tissues were originally screened to identify staining intensity patterns.  Staining 
intensity was graded as follows: 1, weak (faint brown); 2, moderate (brown); 3, intense (dark 
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brown/black).  The values for percent epithelial staining and staining intensity were 
combined to give an immunohistochemical score for each animal.   
RNA Analysis 
Total RNA was isolated from whole lung tissue via Trizol according to 
manufacturer’s guidelines (Invitrogen, Carlsbad, CA).  Following RNA isolation, the pellets 
were resuspended in nuclease free water and heated at 65°C for 5 min.   
One-Step Real-Time qPCR:  RNA samples were assessed for quantity and purity by 
spectrophotometry at 260nm and 280nm and were DNase treated (TURBO DNase, Ambion) 
and diluted 1:10 with nuclease-free water for one-step real-time qPCR.  Reactions were 
carried out using SuperScriptTM III Platinum® One-Step quantitative RT-PCR System with 
ROX kit (Invitrogen, Carlsbad, CA).  A test plate was run using a mixture of all RNA 
samples serially diluted, to determine the optimal dilution range for each target standard 
curve and individual sample dilutions.  Following determination of the optimal dilution range 
for each target, samples and standards were run in duplicate (18).  Ovine primers and probe 
were used to detect VEGF, VEGF R-1 and VEGF R-2.  The primers and probe for VEGF 
detected VEGF isoforms120, 164, and 187 (Table 1).  Each target gene amplification was 
converted to a relative quantity using a target specific standard curve and normalized to two 
endogenous reference genes, ovine ubiquitin and ovine ribosomal S15 (17).  
Gel Electrophoresis:  Using the 260nm absorbance readings the samples were diluted to the 
same RNA concentration (111 ng/μl).  Total RNA was reverse transcribed using 
SuperScriptTM III (Invitrogen, Carlsbad, CA) and random pentadecamers (Integrated DNA 
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Technologies, Coralville, IA).  The following primer set was used to amplify the cDNA for 
ovine VEGF products:  VEGF forward:  5'-GCCAGCACATAGGAGAGATGAG, VEGF 
reverse: 5'-TGTTCTGTCGATGGTGGTGGTG.  These primers were predicted to produce 
PCR products of 166bp, 278bp, 370bp, 436bp for sheep VEGF isoforms 120b, 120, 164, and 
187 respectively.  PCR amplification of cDNA was performed in an Eppendorf Mastercycler 
using TaKara Ex Taq (Takara, Madison, WI).  PCR products were separated in a 2% 
agarose/TAE with GelRed stain (Biotium, Hayward, CA).  Imaging and densitometry was 
performed using an Alpha Innotech Imager with AlphaEaseFC software. 
Vascular endothelial growth factor (VEGF) protein analysis by ELISA 
Whole lung was homogenized on ice in T-PER (Tissue Protein Extraction Reagent, Pierce, 
Rockford, IL) along with a Complete TM Protease Inhibitor Cocktail (Santa Cruz 
Biotechnology, Santa Cruz, CA).  The TPER directions were followed using 0.5 grams of 
lung tissue to 5 ml of TPER reagent.  Supernatants from the homogenization were assayed 
using a VEGF-A enzyme-linked immunosorbent assay, which recognizes VEGF120 and 
VEGF165 (Invitrogen, Carlsbad, CA).  Samples were run in duplicate and expressed as 
picograms VEGF per gram of lung tissue. 
Western blotting 
Whole lung from each animal was homogenized on ice in TPER along with a cocktail of 
protease inhibitors.  Protein concentration was determined using the bicinchoninic acid 
protein assay reagent kit (Pierce, Rockford, IL). Samples were resuspended in sodium 
dodecyl sulfate (SDS) sample buffer and heated to 100ºC for 5 minutes, and resolved by 8-
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16% polyacrylamide gels (Pierce, Rockford, IL).  After electrophoresis, proteins were 
transferred to a polyvinylidene fluoride Immobilon-P membrane (Millipore, Bedford, MA) 
and blocked with 3% bovine serum albumin in PBS 0.05% Tween 20 (PBST) for one hour at 
room temperature.  After blocking, membranes were incubated overnight at 4ºC with the 
specified primary antibody: mouse monoclonal anti-VEGF (clone VG-1, 1:2000) (Millipore, 
Bedford, MA), mouse monoclonal anti-VEGFxxxb ( MAB3045 at 1:2000) (R&D systems, 
Minneapolis, MN) , or anti-β-actin (1:10,0000) (Sigma, St. Louis, MO).  After 3 washes in 
PBST, membranes were incubated with an Alexa Fluor 488 conjugated goat anti-mouse 
secondary antibody (1:2000) (Invitrogen, Carlsbad, CA).  After 3 washes in PBST, 
fluorescent signal was detected by a Typhoon 8600 imaging system (GE Healthcare, Quebec, 
Canada).  When necessary, membranes were stripped using a stripping buffer containing 62.5 
mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM β-mercaptoethanol at 50°C for 30 min. 
Sequencing: 
PCR products were cloned into pCR4TOPO sequencing vector (Invitrogen, Carlsbad, CA), 
according to the manufacturer’s instructions.  Colonies resulting from the TOPO cloning 
reactions were screened for VEGF inserts by performing colony PCR using the primers for 
the splice isoform screening.  Positive clones were cultured overnight and plasmid DNA was 
isolated the next day and submitted for sequencing to the Iowa State University DNA 
sequencing facility. 
Statistical Analysis 
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Statistical analyses were performed with commercially available statistics software 
(GraphPad Prism, GraphPad Software, San Diego, CA).  Data was analyzed for normal 
distribution and log transformed when necessary.  Comparisons were done using one-way 
ANOVA followed by Tukey’s post-test analysis.  Immunohistochemical data was analyzed 
using a Kruskal-Wallis test and a Dunn multiple-comparison posttest. Data are represented as 
means (±SEM).  A P value <0.05 was considered significant. 
Results 
VEGF and VEGF receptor mRNA expression 
VEGF mRNA expression was highest at 115 days gestation with a decrease in 
expression at 130 days gestation and term (Figure 1).  Expression increased at 15 days post-
birth but was low in adult lung.  VEGF R-1 expression in the lung was high at 115 days 
gestation but decreased at term and was lowest at 15 days post-birth (Figure 2).  Expression 
of VEGF R-1 in adult lung was similar to expression during prenatal development.  VEGF R-
2 expression was low at 115 days gestation with increased expression at 15 days post-birth 
(Figure 3).  Expression of VEGF R-2 in adult lung was similar to expression levels at 130 
days gestation and term.  
VEGF isoform expression 
 Expression of VEGF isoforms; VEGF120, VEGF164, VEGF187 and VEGF120b were 
measured in lung at 115 days gestation, 130 days gestation, term and adult via PCR 
amplification (Figure 4 A).  VEGF120 was highly expressed at 115 days and 130 days 
gestation compared to term and adult (Figure 4 B).  VEGF164 was highly expressed at 115 
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and 130 days gestation with low expression at all other time-points (Figure 4 C).  VEGF187 
was highly expressed at 130 days gestation with a decrease at term and in adult lung (Figure 
4 D).  VEGF120b did not change significantly (Figure 4E ).  VEGF187 was the predominant 
isoform at all developmental time points but not in the adult lung (Figure 5).  VEGF120b was 
the predominant isoform in adult lung. 
VEGF immunolocalization and protein concentration 
VEGF antigen was localized by immunohistochemistry to the cytoplasm of the 
bronchiolar epithelial cells lining the small and medium but not the large bronchioles in all 
age groups.  In adult lung, multifocal alveolar macrophages were immunoreactive for VEGF 
antigen.  Lung at 115 and 130 days gestation had multifocal immunoreactive bronchiolar 
epithelial cells with weak epithelial staining intensity (Figure 6 A, B).  At term and 15 days 
post-birth there were increased number of immunoreactive cells with increased staining 
intensity (Figure 6 C, D).  In the adult lung, VEGF antigen was present within the majority of 
bronchiolar epithelial cells with intense staining (Figure 6 E).  An immunohistochemical 
score was given to each section of lung based on the percentage of immunoreactive epithelial 
cells and staining intensity.  Adult lung had the highest immunohistochemical score and the 
lowest score was in lung from 115 and 130 days gestation (Figure 6 G). 
VEGF187 and VEGF164 were detected consistently in lung tissue by western blot, 
indicating that they are the predominant isoforms in the developing ovine lung (Figure 7 A).  
VEGF protein concentration quantified by ELISA demonstrated high VEGF concentrations 
in adult lung (Figure 7 B).  VEGF protein was also higher at 15 days post-birth compared to 
115 days gestation.  VEGF120b was detected by western blot and demonstrates that this anti-
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angiogenic isoform is significantly expressed throughout pulmonary development (Figure 7 
C). 
Discussion 
VEGF expression in the lung is essential for regulating vasculogenesis during 
development.  VEGF also functions in pulmonary homeostasis following birth and has been 
shown to regulate surfactant protein production (10, 11), reduce apoptosis of epithelial cells 
(31) and may also serve to promote reparative processes following injury (7, 12, 26).  During 
ovine lung development, the angiogenic VEGF isoforms (VEGF120, VEGF164, and VEGF187) 
followed the same pattern – high mRNA levels during prenatal development with a 
significant reduction in expression at term.  Differential pulmonary VEGF isoform 
expression during development has been documented in the mouse, rat and rabbit.  In the rat 
and mouse there is an increase in VEGF188 mRNA prior to birth with a moderate decrease 
following birth, similar to the lamb (19, 27).  In the mouse, VEGF120 and VEGF164 decrease 
prior to birth and remain low 30 days following birth, differing slightly from ovine lung in 
which VEGF120 and VEGF164 mRNA decreased at term.  In the rabbit lung, VEGF165 was 
highly expressed in late fetal development but decreased significantly by 10 days after birth, 
similar to the lamb (39).  VEGF189 expression in the rabbit was high in late fetal lung 
development and remained high following birth, while in the lamb there is marked decrease 
of VEGF187 following birth.  In ovine lung VEGF120b expression remained consistent 
throughout development.  To our knowledge VEGF120b has not been characterized during 
pulmonary development in any other species and because of its inhibitory activity may have 
a key role in VEGF regulation.  The similarities of VEGF isoform expression in rodent, 
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rabbits and in lambs in this study, suggests that developmental regulation of VEGF isoform 
expression in the lung appears to be conserved. 
 There was some inter-animal variability in isoform expression with the term, 15 days 
post-birth and adult groups.  The reason for the variability is unknown, however there may be 
several factors involved.  At the time of birth animals must expand their lungs and begin 
breathing on their own.  Stress or dystocia at parturition could affect pulmonary inflation and 
gas exchange, which may then alter isoform expression.  Also at the time of birth, animals 
are exposed to new environmental airborne substances including particulate material, vapors, 
aerosols, alterations in humidity, microbial products, fumes and other factors that may 
change normal lung homeostasis and alter isoform expression.  Lastly, lambs used in the 
study are out-bred, therefore genetic factors such as single nucleotide polymorphisms in the 
genes themselves or regulatory elements could also play a role in expression levels following 
birth.   
Although VEGF mRNA expression was high during prenatal lung development, with 
decreasing levels after birth, VEGF protein levels were low prenatally and increased towards 
adulthood.  Protein levels were highest in adult sheep, in which there was low VEGF mRNA 
expression.  It is well-known that VEGF transcriptional and translational regulation is 
complex and controlled at many levels.  Hypoxia is the most studied inducer of VEGF 
transcription and mRNA stablility (38) however other factors such as growth factors, 
hormones, and oncogenes activate VEGF transcription (14, 16).   Transcriptional regulation 
occurs at the two promoter regions; promoter one (P1) is located at the 5’-untranslated region 
(5’UTR) and a second internal promoter is located 633 nucleotides downstream from P1 (2).  
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Translation is controlled by the classical AUG initiation codon and alternatively by three 
CUG start codons located within the 5’UTR.  Translation can also be regulated by two 
internal ribosome entry sites (IRES A and IRES B) located upstream of the AUG start codon.  
Regulation of VEGF specific isoform expression is largely unknown.  One study 
demonstrated that the RNA structure of alternatively spliced mRNA controls selection of the 
translation initiation codon (5).  Another study demonstrated an upstream ORF within the 
IRES A that acts as a regulatory element to negatively control isoform (VEGF121) expression 
(3).  A limitation of this study was the inability to quantify isoform specific protein 
expression, due to the lack of isoform-specific antibodies.   
The anti-angiogenic isoform, VEGF120b, was detected via western blot; however the 
functional role of this and other anti-angiogenic isoforms in pulmonary development is 
unknown.  Interestingly, VEGF120b was the only anti-angiogenic isoform detected in ovine 
lung tissue even though the blot was probed with an antibody that should recognize the 
carboxyl terminus of all anti-angiogenic isoforms.  It is possible that VEGF164b is not highly 
expressed and below the limit of detection, indicating that VEGF120b may play a more 
significant role in pulmonary development.  A recent study examining the protein expression 
of VEGFxxxb in normal adult lung and adult lung from ARDS patients demonstrated 
expression of both VEGF121b and VEGF165b (35).  However, the signal from VEGF121b was 
much more intense, indicating that VEGF121b appears to be more prevalent in lung than 
VEGF165b.  Further studies are necessary to examine the role of anti-angiogenic isoforms in 
pulmonary development. 
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VEGF concentrations are critically important in lung development, and rodent models 
overexpressing VEGF in the lung demonstrate lung dysmorphogenesis (1).  Therefore, the 
low VEGF protein concentration in the ovine lung during prenatal development is likely due 
to tight regulation at the translational level to maintain adequate concentrations necessary for 
development.  Several hypotheses can be made regarding the low VEGF mRNA expression 
and high protein concentration in the adult lung.  One hypothesis may be that adult animals 
have more efficient translation at the IRESes, leading to higher protein expression without an 
increase in mRNA expression.  Another hypothesis is that binding of the larger isoforms via 
their heparin-binding sites to the ECM allows VEGF to be present when necessary, without 
increased mRNA expression.   
Differential expression of the VEGF receptors was also present during development.  
Expression of VEGF R-1 decreased following birth but increased in adult lung.  The effects 
of VEGFR-1 are varied depending on developmental stage and cell type (16).  VEGF R-2 is 
the major mediator of the mitogenic and permeability effects of VEGF.  Expression of VEGF 
R-2  was low during prenatal development but increased at 15 days post-birth.  Expression 
was also low in adult lung.  Receptor expression during development is extremely important 
for proper vascular development, however the reason for high VEGF R-2 expression at 15 
days post-birth is not known.  It could be due to the fact that at this stage of life, the lung has 
a converging set of demands that include: growth and further development, function (airflow 
and gaseous exchange), and adaptation to newly encountered environmental substances 
within the air. 
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This study demonstrates that expression of the major VEGF isoforms are 
differentially regulated during ovine pulmonary development and in the adult lung.  
Importantly, the expression of mRNA diverged remarkably from that of the protein profile.  
Identifying isoform specific protein levels of antigogenic (VEGFxxx) and anti-angiogenic 
(VEGFxxxb) isoforms will aid in the understanding of the role of specific isoforms during 
development.  Differential isoform expression and the divergent mRNA and protein levels 
demonstrate the importance and complexity of VEGF regulation in proper pulmonary 
development and homeostasis. 
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Table 1:  Primers and probe sequences for ovine gene expression assessed by one-step real-
time qPCR 
6FAM or VIC, 5’ Fluorescent reporter dye; TAMRA, Fluorescent quencher dye; MGBNFQ, 
Minor groove binding non-fluorescent quencher 
 
 
 
 
 
 
VEGF Fwd: 5'-GCCCACTGAGGAGTTCAACATC 
 Rev: 5'-TGGCTTTGGTGAGGTTTGATC 
 Probe: 5'-6FAMCCATGCAGATTATG-MGBNFQ 
VEGF Receptor-1 Fwd: 5’-TCAGGTGAGCTTGGACAAAATG 
 Rev: 5’-CACCGTGCAAGACAGCTTCA 
 Probe: 5'-6FAM-CTGCGGAAGGAGAG-MGBNFQ 
VEGF Receptor-2 Fwd: 5’-CCAGTGGGCTGATGACCAA 
 Rev: 5’-GCAACAAACGGCTTTTCATGT 
 Probe: 5'-6FAM-AAGAACAGCACGTTCGTCCGGG-TAMRA 
OvRPS15 Fwd: 
Rev: 
Probe 
5’-CGAGATGGTGGGCAGCAT 
5’-GCTTGATTTCCACCTGGTTGA 
5’-VIC-CCGGCGTCTACAACGGCAAGACC-TAMRA 
Ubiquitin (ovine) Fwd: 5'-GGTGGCTGTTAATTCTTCAG 
 Rev: 5'-AAATGGCTAGAGTGCAGAACGAT 
 Probe: 5'-6FAM-TTCATAATGCTCAGTGATGG-MGBNFQ 
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Figures 
 
 
Figure 1:  VEGF mRNA expression was highest in prenatal lamb lung at 115 and 130 days 
gestation and at 15 days post-birth.  The lowest expression of VEGF mRNA was in term 
lamb lung and adult lung.  (DG= days gestation; PB = post-birth)  *p<0.05, ***p<0.001. 
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Figure 2:  VEGR R-1 mRNA expression was highest at 115 days gestation and decreased at 
term.  The lowest expression was at 15 days post-birth.  Expression in adult lung was similar 
to levels present during prenatal development.  (DG= days gestation; PB = post-birth) 
(*p<0.05, ***p<0.001). 
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Figure 3:  VEGF R-2 mRNA expression in the lung was low at 115 days and 130 days 
gestation and at term.  Expression was highest in the lung at 15 days post-birth with 
expression in the adult similar to expression levels throughout prenatal development.  (DG= 
days gestation; PB = post-birth) *p<0.05, ***p<0.001. 
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Figure 4:  VEGF isoform expression in the lung during prenatal, postnatal, and adult lung.  
Relative intensity of VEGF120 (B), VEGF164 (C), VEGF187 (D), and VEGF120b (E) derived 
from densitometry analysis of isoform expression as measured by PCR (A).  There was high 
VEGF120 expression at 115 days and 130 days gestation compared to term and adult.  
VEGF164 was highly expressed at 115 and 130 days gestation with low expression in all other 
groups.  VEGF187 was highly expressed at 130 days gestation compared to term and adult.  
VEGF120b did not change significantly through development and in adult lung.  (DG= days 
gestation; PB = post-birth) *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5:  Percent relative expression of VEGF120, VEGF164, VEGF187 and VEGF120b at 115 
days gestation (DG), 130 days gestation, term, 15 days post-birth (PB) and adult lung.  
VEGF187 was the predominant isoform expressed at all developmental time points but in the 
adult lung.  VEGF120b was the predominant isoform expressed in adult lung. 
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Figure 6:  Immunohistochemistry for VEGF antigen in the ovine lung at 115 days gestation 
(A), 130 days gestation (B), term (C), 15 days post-birth (D) and adult (E).  Isotype control 
(F).  VEGF immunoreactivity was present in the cytoplasm of bronchiolar epithelial cells 
lining the medium and small bronchioles.  Multifocal alveolar macrophages were 
immunoreactive for VEGF antigen.  The lungs were scored based on number of epithelial 
cells positive for the antigen and staining and staining intensity (G).  Antigen staining at 115 
and 130 days gestation had fewer immunoreactive epithelial cells and weaker staining 
intensity compared to term, 15 days post-birth and adult lung.  (DG= days gestation; PB = 
post-birth) 
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Figure 7:  Western blot on lung tissue using an antibody against VEGF-A demonstrating 
expression of VEGF164 and 187 in developing lung (A).  B.  ELISA performed on ovine lung 
homogenates demonstrates VEGF protein expression was highest in adult lung with low 
expression at 115 days gestation, 130 days gestation and term.  C.  Western blot using an 
antibody against VEGFxxxb antibody demonstrates VEGF120b is expressed in developing and 
adult lung.  (DG= days gestation; PB = post-birth) *p<0.05, **p<0.01, ***p<0.001. 
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CHAPTER 5: GENERAL CONCLUSIONS 
 RSV is the leading cause of bronchiolitis in infants and infects almost 100% of 
children by age 2.  The only licensed therapy is a prophylactic monoclonal antibody used to 
treat infants at high risk but there is currently no licensed vaccine and no fully effective anti-
viral drug [1].  High risk infants include those born prematurely, infants with 
cardiopulmonary disease and infants with an immune deficiency [2, 3].  The innate immune 
response is very important in infants as their adaptive immune responses are immature and 
not fully effective [4].  The work in this dissertation:  1) characterizes a lamb model of RSV 
disease using the A2 strain of human RSV to develop an ovine model of RSV disease and to 
measure the epithelial innate immune response to RSV infection, 2) examines the effect of 
VEGF pretreatment on RSV disease severity and enhancement of the pulmonary innate 
immune response, and 3) defines developmental VEGF isoform and VEGF receptor 
expression in the ovine lung. 
RSV Lamb Model 
 Although there are several animal models used to study RSV disease, there is no one 
model that fully replicates human pulmonary pathology and clinical signs.  Mice are the most 
widely used animal model but are not very permissive to RSV infection.  Pulmonary lesions 
in mice do not adequately represent human infection as pulmonary inflammation is centered 
on vessels, and not on airways as it is in humans [5].  Also, lung alveolar development, 
airway branching patterns, and airway cell content in mice differ from human and lambs [6].  
The first study in this dissertation demonstrated that lambs were susceptible to a human RSV 
strain (strain A2) and exhibited clinical signs and pulmonary pathology similar to human 
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RSV disease.  Pulmonary lesions included suppurative bronchiolitis with locally extensive 
alveolar consolidation and infiltration of lymphocytes and plasma cells with syncytial cell 
formation.  Peak lesions were present at 6 days post-infection with lesion resolution at day 
14.  RSV antigen was present in the cytoplasm of bronchiolar epithelial cells, type II 
pneumocytes, and alveolar macrophages.  RSV induced the expression of important 
epithelial innate immune genes, SP-A and SBD-1, demonstrating modulation of epithelial 
responses by the virus.  In conclusion, infection with a human strain of RSV in the neonatal 
lamb reproduces the pulmonary pathology found in human infection and modulates epithelial 
innate immune responses.  Replication and disease caused by this laboratory-adapted strain 
suggests that RSV strains with more virulence may induce enhanced disease.  The lamb 
model will be beneficial for future investigations of pathogenesis, assessing viral virulence, 
and development of therapeutic compounds. 
Exogenous VEGF Administration Decreases RSV Disease Severity 
 The second study examined the protective effect of VEGF pretreatment on RSV 
disease in the lamb model.  VEGF is a well-known regulator of vasculogenesis that functions 
as an endothelial cell mitogen and vascular permeability factor in physiologic and pathologic 
angiogenesis [7].  In addition, VEGF is highly expressed in the lung and serves an essential 
role in pulmonary development, surfactant homeostasis and pulmonary repair processes [8, 
9].  VEGF also increases surfactant protein production [10].  Surfactant protein is important 
in both lung maturation and innate immunity.  Surfactant proteins-A and -D (SP-A and SP-D 
respectively) are collectins produced by epithelial cells and are found in the airway surface 
liquid [11].  Collectins modulate inflammatory responses within the lung to minimize 
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inflammatory-induced damage to maintain function.  The collectins also aggregate and 
opsonize pathogens for enhanced clearance [12].  Mice deficient in SP-A and SP-D have 
decreased RSV clearance and increased pulmonary pathology as a result [13].  Human 
infants with polymorphisms in SP-A have increased RSV disease severity [14]. 
 In this study, we hypothesized that VEGF would enhance the pulmonary innate 
immune response and thereby decrease RSV disease severity.  Lambs were pretreated with 
human recombinant VEGF (rhVEGF) prior to RSV infection.  Animals were sacrificed at 2, 
4 and 6 days following infection to determine VEGF pretreatment effect on disease severity, 
alteration in important epithelial innate immune genes (SP-A, SP-D, sheep β-defensin-1), 
epithelial inflammatory products (TNFα, IFNβ, IL-6, IL-8) and endogenous VEGF and 
VEGF receptor expression.  Pretreatment with rhVEGF decreased bronchiolitis, airway 
occlusion and alveolar consolidation at 6 days post-infection.  Pretreatment with rhVEGF 
increased SP-A and SBD-1 expression exhibiting regulation of key epithelial innate immune 
genes by rhVEGF.  RSV infected lambs pretreated with rhVEGF had increased cellular 
proliferation at 4 days post-infection.  In conclusion, this study demonstrates that 
administration of rhVEGF prior to RSV infection significantly reduces RSV disease severity 
by decreasing pulmonary pathology, enhancing innate immune responses and increasing 
cellular proliferation.   
Differential Expression of VEGF and VEGF Receptors Throughout Development 
 The third study measured the expression of VEGF and VEGF receptors during ovine 
pulmonary development and in the adult ovine lung in order to define differential 
developmental expression patterns.  VEGF is necessary for proper embryologic development 
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and lung development.  Mice lacking even one allele of VEGF die during embryonic 
development with defects in vascular formation [15, 16].  When VEGF is inhibited during 
lung formation, epithelial cell proliferation halts and cells undergo apoptosis [17].  VEGF 
pre-mRNA is spliced into different mRNA molecules yielding various polypeptide isoforms 
that are either angiogenic (VEGFxxx) or anti-angiogenic (VEGFxxxb) [18].  VEGF and VEGF 
receptors are expressed by bronchiolar epithelial cells, type II epithelial cells and alveolar 
macrophages [19, 20].  Pulmonary functions of VEGF include structural development, 
surfactant homeostasis and pulmonary reparative process, as previously mentioned.    
In this study, the mRNA for expression of the angiogenic VEGF isoforms; VEGF120, 
VEGF164, and VEGF187 and one anti-angiogenic isoform, VEGF120b, were measured at 115 
days gestation, 130 days gestation, term, 15 days post-birth and in adult lung.  Overall, there 
was high expression of the angiogenic isoforms prior to birth with a decrease at birth.  The 
anti-angiogenic isoform, VEGF120b, did not change significantly throughout development.  
Interestingly, VEGF187 was the predominant isoform present during all developmental 
periods except the adult lung, in which VEGF120b was the predominant isoform.  VEGF 
receptors-1 and -2 were also differentially expressed.  Protein concentrations (VEGF164 and 
VEGF187) were high in adult lung but low at all other developmental periods, significantly 
diverging from mRNA expression levels.  In conclusion, this study demonstrates that 
expression of the major angiogenic VEGF isoforms are differentially regulated during ovine 
pulmonary development and in the adult lung.  High VEGF mRNA expression did not 
correlate to increased protein concentration, signifying the importance and complexity of 
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VEGF transcriptional and translational regulation in normal pulmonary development and 
homeostasis. 
Future Research Directions 
 These studies demonstrate that pretreatment with rhVEGF decreased RSV pulmonary 
pathology and enhanced epithelial innate immune responses.  Future studies should address 
rhVEGF administration after RSV infection or disease onset, to determine if rhVEGF could 
have therapeutic potential in patients already exhibiting clinical signs.  These studies 
addressed VEGF’s effect on epithelial innate gene expression; however VEGF has other 
functions that should be investigated, such as macrophage chemoattraction that may serve to 
modulate the immune response to infection and its ability to increase vascular leakage of 
serum from vessels.  The mechanistic basis by which rhVEGF reduces severity of RSV 
infection is likely multifactorial.  In vitro studies could be used to address its effects on 
epithelial protection and viral replication. 
 We also demonstrated that expression of VEGF during pulmonary ontogeny is 
developmentally regulated.  Future experiments should determine if there are changes in 
VEGF isoform expression during RSV infection that may alter pulmonary development and 
homeostatic functions.  Alteration in expression should then be confirmed at the protein 
level, if and when antibodies are available for the specific isoforms.  Identification of 
isoform-specific alteration during RSV infection may be beneficial for therapeutic design and 
will aid in furthering our understanding of the role of specific isoforms during infection.  
This information may be helpful not only in preventing or reducing severity of RSV 
infection; but perhaps also in enhancing lung maturity in premature infants. 
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